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 The tumor suppressor p53 is the single most altered gene in human cancers. p53 
homologues, p63 and p73 play a major role in development and in human cancer. Both 
p63and p73-null mice exhibit profound developmental abnormalities, suggesting a vital 
role for p63 and p73 in development. Although the role of p73 in human cancers is well 
established, the role of p63 still remains to be understood. While p63 plays a major role 
in development, p73 plays a major role in tumor suppression as well as in development. 
Although a functional co-operation is evident between each member of p53 family, 
additional studies are required to understand the functional cross-talk between each 
member of the p53 family, and their ability to govern multiple biological functions. 
Identifying common and specific transcriptional networks of p53 family is essential for 
understanding the existing functional co-operation between each member.  
 This dissertation focuses on defining the functional relevance of the regulation of 
vitamin D receptor (VDR) by p53 family members. Secosteroid hormone vitamin D, 
through its cognate receptor VDR, regulates genes involved in mineral homeostasis, bone 
formation and in epidermal differentiation. Vitamin D and its analogues also exhibit anti- 
proliferative activities and are widely used as cancer chemotherapeutic agents. Findings 
from this study demonstrated VDR as a direct target of p63 and p73; however p53 does 
not appear to regulate VDR directly or indirectly.  One part of this dissertation 
underpinned the role of VDR in p63 mediated biological functions. Down regulation of 
endogenous p63 in human epidermoid cancer cells resulted in complete loss of 
 iv
endogenous VDR expression. In addition, up-regulation of VDR by p63 appears to 
inhibit the migration and invasion of human epidermoid cancer cells. the second part of 
this dissertation is involved in understanding the p73 mediated regulation of VDR in 
vitamin D-mediated differentiation. Findings from this section of study demonstrated that 
DNA damage-induced expression of VDR is dependent on p73. In addition, p73 was 
proven to be essential for vitamin D mediated osteoblastic differentiation. Furthermore, 
we demonstrated that DNA damage sensitized the cells to vitamin D mediated 
differentiation through p73.  Taken together, while understanding the regulation of VDR 
by p63 will provide new insights on the molecular mechanisms of p63 biology, 
determining the role of p73 in vitamin D-mediated differentiation may aid in vitamin D 
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   I. INTRODUCTION AND PURPOSE  
A. p53 in cancer and chemosensitivity 
 Transcription factor p53 is the most altered gene in human cancers and is 
considered as the guardian of genome (Lane, 1992). Since, mice deficient for p53 are 
tumor prone and p53 function is lost in a majority of human cancers due to the mutations 
or inactivation by its negative regulators, p53 is considered as the classical tumor 
suppressor (Donehower et al., 1992; Hollstein et al., 1991). Primarily, p53 promotes cell 
cycle arrest, apoptosis, DNA repair, cellular senescence and inhibition of angiogenesis 
through the transcriptional regulation of target genes (Giaccia and Kastan, 1998); 
however, the induction of apoptosis and cell cycle arrest by p53 can also occur through 
non-transcriptional mechanisms (Mihara et al., 2003). Stabilization of p53 protein occurs 
in response to various stress stimuli including DNA damage, viral infection or oncogenic 
activation (Schuler and Green, 2001). Once activated and depending on the stimuli, p53 
controls the signaling pathways involved in cell cycle arrest (G1 and G2 cell cycle 
arrest), senesence or apoptosis (Figure 1) (Levine et al., 2004; Vousden, 2000). Strategies 
involved in activation of the p53 pathway to promote tumor suppression are considered to 
be effective anticancer therapies and numerous p53 based cancer therapuetics are in 
preclinical studies. However, alternative p53 independent strategies are required for 






























         
 
Figure 1: Schematic representation of subset of p53 functions.  The activated p53 












B. Structure of p63/p73 
 Although the functional significance of p53 and its interacting proteins has been 
studied extensively, it was not until 1997, that the functional homologues of p53, namely 
p63 and p73 were discovered (Kaghad et al., 1997; Yang et al., 1998). Since their 
discovery, both these genes gained enormous scientific interest, as proteins encoded by 
these genes are functionally more similar to each other than to p53 (Deyoung and Ellisen, 
2007). All three homologues contain similar functional domains namely N-terminal 
Transactivation (TA), central DNA binding and C-terminal oligomerization domains 
(Harms et al., 2004; Levrero et al., 2000). The DNA binding domains of p63 and p73 
show the highest homology (65%) with p53 DNA binding domain (De Laurenzi and 
Melino, 2000). The oligomerization domain of p63 and p73 also show homology (35%) 
with p53 oligomerization domain and like p53, both p63 and p73 exist as tetramers 
through the oligomerization domain (Yang and McKeon, 2000).  The N-terminal 
transactivation domain (TA domain) of p63 and p73 show the lowest homology (25%) 
with p53 transactivation domain. Like p53, the transactivation domain in p63 and p73 is 
essential for the transcriptional potential, as the TA domain interacts with various co-
activators to modulate transcription. Like p53, both p63 and p73 also generate multiple 
transcripts due to the alternative promoter usage and pre-mRNA splicing (Kaghad et al., 
1997; Yang et al., 1998). As a consequence of promoter usage both p63 and p73 
generates either transactivation domain containing isoforms (TAp63 and TAp73) or N-
terminally truncated isoforms (∆Np63 and ∆Np73) (Scoumanne et al., 2005). 










Figure 2: Schematic representation of p63 and p73 gene structures. A) The degree of 
homology between the conserved domains of p63/p73 with p53. B) Multiple isoforms of 
p63/p73 are generated from alternative promoters (P1 and P2) and pre-mRNA splicing. 
The full length TA isoforms and truncated ∆N isoforms are generated from P1 or P2 
promoter respectively. The 3’ pre-mRNA splicing results in additional isoforms α,β and 
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 multiple carboxyl-terminal variants, α, β and γ of p63 and α, β, γ, ε and δ of p73 
(Kaghad et al., 1997; Yang et al., 1998) (Figure 2). The features that distinguish p63 and 
p73 from p53 are the presence of two additional domains, a SAM domain (Steric α 
Motif), and a TID domain (Transactivation Inhibition Domain) in alpha isoforms of both 
p63 and p73 (Moll, 2003; Moll et al., 2001) (Figure 2B). The precise function of TID 
domain and SAM domain in p63 or 73 is still unclear; however, the presence of TID 
domain lowers the transactivation potential of TAp63α and TAp73α isoforms (Serber et 
al., 2002; Thanos and Bowie, 1999). In general, the SAM domain is observed in proteins 
involved in development and is believed to be involved in protein-protein or protein –
RNA interactions (Kim and Bowie, 2003).  
 The TA domain containing isoforms of both p63 and p73 are highly homologous 
to p53, and as a result, TA isoforms act as tumor suppressors like p53 (Harms et al., 
2004). Although, ∆Np63 isoforms lack the full length N-terminal transactivation domain, 
like TAp63 isoforms, ∆Np63 isoforms can also transactivate genes via the presence of a 
short unique N-terminal TA domain (Helton et al., 2006; Wu et al., 2005). Additionally, 
both  ∆Np63 and ∆Np73 isoforms inhibit TAp63/TAp73 and p53 functions by acting in a 
dominant negative manner towards TAp73/TAp73 isoforms and p53 (Stiewe et al., 
2002b). The inhibitory activity of ∆Np63/ ∆Np73 isoforms involve direct competition of 
DNA binding through the formation of hetero-oligomeric complexes (Grob et al., 2001; 
Stiewe et al., 2002a). 
C. Roles of p63/p73 in development and differentiation 
 Gene knock-out studies by multiple groups in mice implicated a broad role for 
p63 and p73 in development and differentiation. p63-null mice are born with severe 
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developmental defects and die shortly after birth due to dehydration (Mills et al., 1999; 
Yang et al., 1999).  Defects observed in p63-null mice include, but are not restricted to, 
an under-development of the skin, as wells as a distinct lack of distal components of 
forelimbs, carpals, digits and hind limbs. Although several studies highlighted a critical 
role for p63 in epithelial stratification program, the precise role of TAp63 and ∆Np63 
isoforms in epithelial tissue development and differentiation still remain controversial 
(Koster et al., 2004; McKeon, 2004). Findings by Senoo et al. (2007) show that ∆Np63α 
is the only p63 isoform observed during epithelial morphogenesis, and also ∆Np63α is 
essential for the proliferative potential of already committed epithelial cells, but not for 
terminal differentiation (Senoo et al., 2007). In contrast, Koster et al. (2004) suggests that 
TAp63 is essential for the commitment of ectoderm to epithelial tissue and that ∆Np63 is 
essential for proliferation and terminal differentiation of already committed epithelial 
cells. 
  Furthermore evidence from in vivo genetic complementation studies in p63-null 
mice suggest the requirement of both TAp63 and ∆Np63 isoforms for commitment and 
stratification of epithelial tissue (Candi et al., 2006). Consistent with its role in epithelial 
morphogenesis, mutations in p63 are associated with human developmental defects (Celli 
et al., 1999; van Bokhoven et al., 2001). Notably, p63 mutations are observed in six 
different human developmental syndromes; 1) split hand/foot malformation (SHFM), 2) 
ectrodactyly, ectodermal dysplasia and cleft lip/palate syndrome (EEC), 3) 
ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC), 4) limb mammary 
syndrome (LMS), 5) acro-dermato-ungual-lacrimal-tooth syndrome (ADULT) and Rapp- 
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Figure 3: Schematic representation of p63 mutations observed in diseases. Selective 
germline mutations of p63 are indicated with corresponding human developmental 
syndromes. Mutations are observed in DNA binding domain or SAM domain or 
transactivation inhibitory domain.
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diseases reside in the DNA binding domain and/or in the SAM/TID domains (Figure 3). 
Consistent with the role of p63 in epithelial tissue development, the defects observed with 
p63 mutations are mainly attributed to the aberrations in apical epithelial ridge formation 
(Rinne et al., 2007; van Bokhoven and McKeon, 2002).  
 Similar to p63, p73 also plays a distinct role in development, particularly in 
neurogenesis and sexual behavior (Yang et al., 2000). Unlike p63 null mice, severe 
neurlogical defects are observed in p73 null mice. p73 null mice have a high mortality 
rate and show a runting phenotype. The death of p73 null mice was associated with 
massive gastrointestinal haemorrhages. In addition, p73 null mice had severe 
immunological problems distinguished by chronic infections and inflammations. p73 null 
mice were born with severe hydrocephalus due to the defects in production or 
reabsorption of cerebral spinal fluid. Additionally, p73 null mice lacked sexual interest, 
due to the defects in pheromone detection. Interestingly, TAp73 isoform specific 
deficient mice showed severe defects in hippocampal and oocyte development but not in 
neural cell maintenance, indicating an isoform specific function for p73 during 
embryonic development (Tomasini et al., 2008).  
 Although, the role of p63 and p73 during embryonic development is well studied, 
the precise function of p63 and p73 in differentiation has yet to be determined. Several 
studies indicate the differential effect of TAp63/p73 and ∆Np63/p73 isoforms on 
differentiation in multiple model systems. TAp73 isoforms promote the differentiation of 
keratinocytes and neuroblastomas by activating a number of genes including S100A2 
(Lapi et al., 2006), while, suppression of p57kip2 expression by ∆Np73 results in a 
blockade of myogenic differentiation as well as cell cycle exit in murine myoblasts (Li et 
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al., 2005). TAp63 isoforms promote keratinocyte differentiation by regulating the 
expression of multiple proteins including loricrin, involucrin, Notch and retinoblastoma 
(Cam et al., 2006; Carroll et al., 2006; Nguyen et al., 2006). Precise roles of p63 and p73 
in differentiation can be understood only by delineating the isoform-specific regulation of 
multiple signaling pathways and the functional interaction between each isoform.  
D. p63/p73 roles in tumorigenesis 
 Both p63 and p73 are not considered to be classical tumor suppressors, however, 
both p63 and p73 might contribute to p53-mediated tumor suppression (Flores, 2007).  
Mouse embryonic fibroblasts (MEF’s) from either p73 or p63 ablated mice show reduced 
cell death upon genotoxic stress, suggesting the requirement of p63 and/or p73 for p53 
mediated apoptosis (Flores et al., 2002). Given that DNA damage induces the expression 
of TAp63/p73 isoforms in these MEFs, the reduced apoptosis observed in p63-and/or 
p73-null MEF’s can be attributed to the lack of TAp63/p73 isoforms. An independent 
study using reconstituted thymocytes from different genetically defined mice suggested 
that p63 and p73 are not required for p53 dependant apoptosis, at least in T- cells (Senoo 
et al., 2004). Further monitoring the lymphoma development in same model system 
showed that loss of p63 or p73 do not underpin any growth advantage to p53 deficient 
mice, suggesting that p53 mediated tumor suppression is independent of p63 and/or p73 
(Perez-Losada et al., 2005).  
 Additionally, studies by Keyes et.al. (2005) demonstrated that p63 heterozygous 
mice are not prone to the development of spontaneous tumors or to chemically induced 
tumors. Moreover, fewer tumors were observed in p53+/- and p63+/- compound mice 
than p53+/- mice (Keyes et al., 2006). These observations suggest that p63 might in fact 
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promote tumor progression. Contrastingly, an affirmative role for p63 and p73 in tumor 
suppression came from mice with single allele deletions of p63 and/or p73. Both p63 and 
p73 heterozygous mice have spontaneous tumors in multiple organs, including the colon 
and prostate (Flores et al., 2005). Therefore, the higher frequency of tumor occurrence in 
p63 and p73 heterozygous mice was attributed to the impairment in p53 mediated 
apoptosis. The obvious differences in findings by these two groups might be due to the 
genetic background variation in creating p63 heterozygous mice. Although the role of 
p63 in tumorigenesis still needs to addressed, recent findings have confirmed the role of 
TAp73 in tumorigenesis. Notably, findings by Tomasini et. al. (2008) indicated that the 
TAp73 isoform specific knock out mice were prone to spontaneous as well as chemically 
induced tumors (Tomasini et al., 2008). However, complete lack of p63 and/or p73 
mutations in human cancers refutes the tumor suppressive functions for p63 and p73 
(Sunahara et al., 1999; Yoshikawa et al., 1999). Thus, additional isoform specific knock 
out mice studies are required for both p63 and p73 to further define their roles in 
tumorigenesis. 
E. p63/p73 and human cancers 
 The expression of both p63 and p73 in normal tissue and in human cancers is well 
studied. The expression of p63 is mainly limited to basal layers of normal epithelial 
tissues including prostate, skin, urothelia and cervix (Yang et al., 1998). The majority of 
the normal human tissues studied express p73 at low levels (Kovalev et al., 1998). In the 
majority of human cancers studied, the expression of p63 and/or p73 is either amplified 
or lost. The amplified levels of p63, particularly ∆Np63 isoforms are observed in various 
human cancers including head and neck squamous cell carcinoma (HNSCC), lung 
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carcinoma, esophageal adenocarcinoma, bladder cancers and cervical carcinomas 
(Glickman et al., 2001; Hara et al., 2004; Massion et al., 2003; Park et al., 2000; Quade et 
al., 2001; Sniezek et al., 2004; Wang et al., 2001; Yamaguchi et al., 2000). Although yet 
to be resolved, the overexpression of p63 in these cancers appears to be both dependant 
and independent of genomic amplification (Redon et al., 2001; Yamaguchi et al., 2000). 
In fact, the p63 gene resides in 3q27–28 locus, which is frequently amplified in squamous 
cells carcinomas (Bjorkqvist et al., 1998). While, ∆Np63 isoform expression is amplified 
in squamous cells carcinomas, the expression of TAp63 isoforms is fairly undetectable 
(DeYoung et al., 2006). Moreover, loss of p63 expression was correlated with poor 
prognosis in multiple carcinomas including bladder cancers (Koga et al., 2003). 
 In contrast to p63, the expression of p73 was observed in a majority of the human 
cancers studied (Melino et al., 2002; Moll and Slade, 2004). Particularly, the up 
regulation of the oncogenic ∆Np73 isoform was observed in a large variety of human 
cancers including, neuroblastoma, glioma, breast, colon, ovarian, liver, squamous cell 
carcinomas, chronic lymphoid leukemia (CLL) and acute myelogenous leukemia (AML) 
(Concin et al., 2004; Cui et al., 2005; Dominguez et al., 2006; Dominguez et al., 2001; 
Douc-Rasy et al., 2002; Leupin et al., 2004; Muller et al., 2005; Rizzo et al., 2004; Wager 
et al., 2006). Although the pro-apoptotic TAp73 isoform expression is observed in a 
subset of human tumors, the oncogenic ∆Np73 inhibits TAp73 function to promote tumor 
progression (Muller et al., 2005). Consistent with its oncogenic function, the preferential 
up regulation of ∆Np73 in a subset of breast tumors was correlated with poor prognosis 
(Dominguez et al., 2006). Moreover, inactivation of the TAp73 promoter by methylation 
was reported in lymphoma (Corn et al., 1999; Kawano et al., 1999).Taken together, these 
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findings implicate oncogenic function for ∆Np73 isoforms and a potential tumor 
suppressive function for TAp73 isoforms.  
F. Role of p63 and p73 in apoptosis and chemosensitivity 
 In general, while TAp63 and TAp73 function similar to p53 in promoting cell 
cycle arrest and apoptosis, ∆Np63 and ∆Np73 isoforms functions opposite of p53 to 
promote cell growth. Ectopically overexpressed TAp63 isoforms induce apoptosis and 
cell cycle arrest in cell culture systems (Shimada et al., 1999). TAp63 isoforms can 
promote the inhibition of cell growth in multiple cancer cell lines by inducing pro-
apoptotic genes and at the same time inhibiting pro-survival genes (Kommagani et al., 
2006; Senoo et al., 2002; Shimada et al., 1999; Spiesbach et al., 2005; Wu et al., 2005). 
TAp63 isoform levels are undetected in most human cancers, however, the induction of 
TAp63 levels upon genotoxic stress are shown to determine the chemosensitivity of 
hepatoma cell lines (Gressner et al., 2005; Petitjean et al., 2005).  
 Similar to p63, TAp73 isoforms are also capable of inducing cell cycle arrest and 
apoptosis in multiple cancer cell lines.  Both ectopic TAp73β and TAp73α isoforms 
promote apoptosis, although TAp73β is shown to be slightly more potent than the 
TAp73α isoform (Melino et al., 2002). Unlike p63, endogenous expression of p73 is 
induced upon treatment with a wide variety of chemotherapeutic agents or cytotoxic 
drugs including, adriamycin, cisplatin, etoposide, doxorubicin and bleomycin (Agami et 
al., 1999; Costanzo et al., 2002; Gong et al., 1999; Urist et al., 2004; Vayssade et al., 
2005). Notably, up-regulation of both TAp73β and TAp73α isoforms was observed upon 
DNA damage, however, the predominant p73 isoform induced upon DNA damage is 
TAp73α (Urist et al., 2004). Given the robust response to a wide variety of  DNA 
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damaging agents, inactivation of  p73 confers chemoresistance to multiple cancer cell 
lines (Irwin et al., 2003). Moreover, TAp73 isoforms play a pivotal role in p53-
independent apoptosis particularly TAp73α, which is vital for E2F1-mediated p53-
independent apoptosis of T-cells (Lissy et al., 2000). Since chemotherapeutic agent 
mediated induction of TAp73α and its expression determines the chemoresistance and 
chemosensitivity, TAp73α is considered a potential target for cancer therapeutics (Irwin 
et al., 2003).  
 In contrast to TA isoforms, amplified levels of ∆Np63α and/or ∆Np73α promote 
chemo-resistance in multiple carcinomas by interfering with pro-apoptotic pathways 
(Leong et al., 2007; Rocco et al., 2006). In support of this view, direct physical 
association of ∆Np63α with TAp73 led to a dramatic down regulation of TAp73 
mediated apoptosis in squamous cell carcinomas (Rocco et al., 2006). Taken together, 
these findings underline complex molecular interactions associated with p63 and p73 
isoforms in governing the chemo resistance and chemosensitivity of multiple cancers. 
Nevertheless, additional functional studies are essential to delineate the contribution of 
individual isoforms of p63 and p73 and their interaction in human cancers. 
G. Vitamin D and VDR  
 The secosteroid hormone 1α, 25 Dihydroxyvitamin D3 (1,25(OH)2D3) (vitamin 
D) plays a vital role in maintaining calcium and phosphate homeostasis, in order to 
protect skeletal integrity. Apart from its classical functions, vitamin D also plays a major 
role in differentiation, immunosuppression, and growth inhibition (Bikle, 2004) (Figure 

























Figure 4: Schematic representation of vitamin D signaling pathway. The binding of 
active form of vitamin D to VDR results in activation of VDR. Once activated VDR 
hetrodimerizes with RXR and binds to VDRE within target gene promoters and 
modulates the transcription. The subset of VDR target genes and their tissue specific 
functions are listed. 
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mediated production in skin. The active form of vitamin D, 1α, 25 Dihydroxyvitamin D3 
(1,25(OH)2D3) is synthesized through multiple steps in skin (Holick et al., 1980a; Holick 
et al., 1980b). First, the exposure of skin to UVB irradiation results in production of pro-
vitamin D from 7-dehydrocholesterol, subsequently 25-hydoxyvitamin D3 (25(OH)D3) is 
synthesized by the hydroxylation of vitamin D3 using vitamin D 25-hydroxylase in liver; 
finally, hydroxylation of 25(OH) D3  by CYP27b1 in kidney results in production of 
active form 1,25(OH)2D3   (Lawson et al., 1971; Masumoto et al., 1988). The vitamin D 
active form 1,25(OH)2D3  will be refereed to as vitamin D (VD or VD3) in rest of the 
document. Circulating vitamin D in serum is carried by the vitamin D binding protein 
(DBP) to the nucleus of target tissues (Cooke and David, 1985; Cooke and Haddad, 
1989). Biological functions of vitamin D are mediated by its cognate receptor Vitamin D 
receptor (VDR), a member of the nuclear receptor family. Principally, the vdr gene is 
composed of 14 exons of which two exons cover a 5’-non coding region and eight exons 
(2-9) produce the classical VDR protein (Baker et al., 1988) (Figure 5). Primarily, 
binding of vitamin D to VDR results in hetero-dimerization of VDR with RXR (Retinoid 
X Receptor), subsequently activating VDR. Activated VDR regulates the target genes by 
directly binding to the vitamin D responsive elements (VDRE) in their promoters (Figure 
4) (Nezbedova and Brtko, 2004). 
H. Vitamin D and VDR functions 
 The anti-proliferative actions of vitamin D and its analogues are demonstrated in 
many different human cancer cell lines (Gombart et al., 2006), notably, cancer cell lines 
from colon, prostate and breast (Guzey et al., 2002; Kane et al., 1996; Koike et al., 1997). 
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Figure 5: Schematic representation of vitamin D receptor gene, mRNA and protein. 
The structural organization of the human VDR gene (DNA) and the exons of 
corresponding full length transcript (mRNA). Exons 1f, 1e, 1d and 1d are untranscribed 
and exons 1a and 1c are part of 5’ untranslated region. Modular structure of VDR protein 
(protein) with functional domains and the location of DNA and ligand binding domains 
are illustrated. 
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growth inhibition, while down-regulating pro-proliferative genes (Banerjee and 
Chatterjee, 2003); Vitamin D and VDR regulate genes involved in cycle arrest including 
p21, p27, PTEN and Rb (Bouillon et al., 2006; Hisatake et al., 2001; Huang et al., 2004; 
Liu et al., 1996; Moffatt et al., 2001). Several other genes involved in growth inhibition 
are also regulated by VDR including, BRAC1, GADD45 and IGFBP-3 (Boyle et al., 
2001; Campbell et al., 2000; Campbell et al., 1997; Jiang et al., 2003; Stewart and 
Weigel, 2005). Since VDR expression is observed in virtually all tissues, vitamin D 
exhibits anti-proliferative actions in most human cancer cell lines. Thus, vitamin D and 
its analogous are extensively used for cancer chemotherapy, specifically for prostate, 
breast and colon cancers. Combinatorial use of vitamin D and its analogues with 
chemotherapeutic agents have shown to be more potent in promoting growth inhibition 
than using either of them alone (Hershberger et al., 2002; Moffatt et al., 1999). In fact, 
clinical trials are underway testing the combinatorial use of vitamin D analogues and 
chemotherapeutic agents for cancer chemotherapy (Fakih et al., 2007; Trump et al., 
2006).  
 Vitamin D and VDR promote differentiation of several human cancer cell lines by 
regulating multiple signaling pathways, including the β-catenin pathway (Palmer et al., 
2001; Palmer et al., 2003). Vitamin D and its analogues also promote osteoblastic 
differentiation, particularly, the differentiation of osteosarcoma cell lines including MG-
63 (Finch et al., 2001). The molecular mechanism of vitamin D-mediated osteoblastic 
differentiation involves the activation of cell cycle inhibitors (p21) and differentiation 
markers (Zenmyo et al., 2001), specifically, the direct transcriptional regulation of 
osteopontin and osteocalcin (Paredes et al., 2004; Shen and Christakos, 2005).  
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 Extensive in vitro studies implicate a novel role for VDR in promoting calcium 
mediated keratinocyte differentiation (Bikle, 2004; Bikle et al., 2004). An increase in 
intracellular calcium levels is a critical molecular event during keratinocyte 
differentiation and is modulated by elevated levels of calcium receptors and phopholipase 
C. Since functional VDRE elements are found in the calcium receptor and in 
phopholipase C promoters, VDR-mediated induction of calcium receptor and 
phopholipase C is believed to be essential for keratinocyte differentiation (Pillai et al., 
1995; Xie and Bikle, 1997; Xie and Bikle, 2001). Additionally, depletion of VDR 
expression levels in primary keratinocytes results in concomitant decrease in the 
expression of keratinocyte differentiation markers including involucrin, profilaggrin, and 
loricrin (Bikle et al., 2002; Hawker et al., 2007). In vivo studies from VDR-deficient mice 
further strengthen the role of VDR in epidermal differentiation; the ablation of VDR 
leads to development of alopecia due to the defects in hair follicle regeneration (Xie et 
al., 2002), and reduced expression of epidermal differentiation markers including 
involucrin, proflaggrin, and loricrin (Xie et al., 2002).  
I. Regulation of VDR 
 Although numerous studies characterized the functional significance of VDR in 
multiple cellular processes, the molecular regulation or the transcriptional regulation of 
VDR is poorly studied. Transcript levels of VDR are modulated by several growth factors 
and cytokines including parathyroid hormone (PTH), thyroid hormone, glucocorticoids 
and retinoic acid (Chen et al., 1983; Chen and Feldman, 1985; Krishnan et al., 1995; 
Krishnan and Feldman, 1991b; Mahonen et al., 1991; Petkovich et al., 1984). 
Interestingly, while activated protein kinase A induces the VDR expression, activated 
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protein kinase C down regulates VDR expression, indicating a homeostatic regulation of 
VDR mediated responses (Krishnan and Feldman, 1991a; Krishnan and Feldman, 1992). 
Additionally, recent studies showed the transcriptional regulation of VDR by several 
transcription factors including Wilms’ tumor suppressor protein (WT1), Caudal-type 
homeobox protein 2  (Cdx-2), SNAIL, and ZEB, SP1 and ß-catenin (Lazarova et al., 
2001; Maurer et al., 2001; Palmer et al., 2004; Shah et al., 2006; Wietzke et al., 2005; 
Yamamoto et al., 1999). Interestingly, transcriptional regulation of VDR through an auto 
feedback mechanism by 1,25-dihydroxyvitamin D3 was reported in a tissue specific 
manner (Zella et al., 2006). Although all these studies gave a preliminary insight on the 
regulation of VDR, additional studies are essential in understanding the cell and tissue 
specific regulation of VDR by key signaling components. 
J. Rationale and Significance 
 Identifying new transcriptional networks of p53 family members will provide 
significant insight into the functional diversities of each member. Furthermore, 
understanding the functional cross-talk between each member of p53 family, based on the 
regulation of common and unique target genes, will be crucial to deciphering their role in 
tumorigenesis and development. Understanding the diverse biological affects exerted by 
p63 and p73 through common target genes will shed light on the functional co-operation 
between p63 and p73.  The secosteroid hormone vitamin D exerts its biological actions 
through its cognate receptor VDR. Although extensive work has been carried out on the 
biological function of vitamin D and its analogs, little is known about the transcriptional 
regulation of VDR. This dissertation work focuses on the transcriptional regulation of 
VDR by members of p53 family. The initial studies from this dissertation demonstrate 
that VDR is induced by p63 and p73, but not by p53. My hypothesis is that, 1) regulation 
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of VDR by p63 is coupled with the inhibition of invasiveness of squamous cell carcinoma 
cells 2) p73 mediated regulation of VDR is essential for vitamin D-mediated osteoblastic 
differentiation. Thus, understanding the transcriptional regulation of VDR by p63 and 
p73 and their implication on vitamin D-mediated biological activities, will aid in vitamin 
D based cancer chemotherapeutic strategies. Moreover, understanding the role of VDR in 
p63 and/or p73 mediated biological activities will shed light on the molecular mechanism 









II. MATERIALS AND METHODS 
A. Cell Lines, Reagents and plasmids 
 Human non-small cell lung carcinoma cell line (H1299), human cervical 
carcinoma cell line (HeLa), human osteosarcoma cell line (SaOS2) and human 
epidermoid carcinoma cell line (A431) were obtained from ATCC. All the cells were 
maintained in Dulbecco’s modified eagle medium (DMEM) with 8% fetal bovine calf 
serum (FBS) and 250 U of penicillin and 250 µg of streptomycin (PS) at 37°C in 5% 
CO2. Primary mouse embryonic fibroblasts (MEF) obtained from wild-type or p63–/– 
mice were kindly provided by Dr. Elsa Flores (University of Texas M.D. Anderson 
Cancer Center, Houston, TX). The active form of vitamin D, 1α, 25-dihydroxyvitamin D3 
(VD3) (Sigma, Inc.) was prepared as 10 mM solution in 100 % ethanol. Doxorubicin 
hydrochloride (Sigma, Inc.) was prepared in water as 100 mM solution and etoposide 
(Sigma, Inc.) was prepared as 50 mM solution in dimethyl sulfoxide (DMSO) (Sigma, 
Inc.). Expression plasmids encoding TAp63γ, TAp63γ (R279H) mutant and TAp63α 
were constructed in pcDNA3.1A vector as described earlier (Caserta et al., 2006). 
Expression plasmids encoding ∆Np63γ and ∆Np63α were kindly provided by Dr. Frank 
McKeon (Harvard Medical School, Boston, MA) and TAp73β, ∆Np73β and TAp73α, 
TAp63β and ∆Np63β were kindly provided by Dr. Xinbin Chen (University of Alabama, 
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Birmingham, AL). p53 and p14ARF expression plasmids were a generous gift from Dr. 
Steven Berberich (Wright State University). VDRE-Luc reporter was a generous gift 
from Dr. Alberto Munoz (University of Madrid).  
 VDR-Luc reporter construct was constructed by amplifying the -1500 to -1 region 
(Accession no # AB002168) upstream of the VDR open reading frame using BAC clone 
RP11-254E3 (BACPAC Resources) and subsequently the -1500 to -1 region was cloned 
into promoter-less pGL3 Basic vector (Promega, Inc.) into the Kpn I and Hind III sites. 
The primers used for amplifying -1500 to -1 region, are as follows, sense 5’- CGG GGT 
ACC CGA TGC TTT GGG CAA GG –‘3 and anti sense 5’- CCC AAG CTT AGA CAG 
CCC AGC ACC TGG CC –‘3. The three different VDR promoter deletion constructs 
were generated by amplifying the desired region within VDR promoter region from 
VDR-Luc construct and subsequently cloned the region into promoter-less pGL3 Basic 
vector (Promega, Inc.) at Kpn I and Hind III sites. The primers used for amplifying -1267 
to -1 region of VDR promoter were as follows, sense 5’- CGG GGT ACC TGT TGG 
AAG GTT CTT CCT TC –‘3 and anti sense 5’- CCC AAG CTT AGA CAG CCC AGC 
ACC TGG CC –‘3. The primers used for amplifying -1060 to -1 region of VDR promoter 
were as follows, sense 5’- CGG GGT ACC TGT TGG AAG GTT CTT CCT TC –‘3 and 
anti sense 5’- CCC AAG CTT AGA CAG CCC AGC ACC TGG CC –‘3. The primers 
used for amplifying -765 to -1 region of VDR promoter were as follows, sense 5’- CGG 
GGT ACC TGT TGG AAG GTT CTT CCT TC –‘3 and anti sense 5’- CCC AAG CTT 
AGA CAG CCC AGC ACC TGG CC –‘3. The -631/-585 region of VDR promoter 
containing luciferase construct, VDR shRNA and NSC (non silencing control) shRNA 
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constructs were generated by Dr. Madhavi Kadakia (Kommagani et al., 2006; 
Kommagani et al., 2007).  
B. Transient transfections 
 Cells were seeded onto 6-well plates prior to day of transfections unless otherwise 
indicated. At around 80% confluency, transient transfections were performed using 
Lipofectamine 2000 reagent (Invitrogen, Inc.) with desired plasmids in serum free 
DMEM. After 5 hr incubation the medium was replaced with DMEM supplemented with 
FBS and PS. For all the studies a total of 3 µg of desired expression plasmids were used 
and in a given experiment total amount of plasmids was adjusted to 3 µg using empty 
vector.  
C. Real time quantitative PCR 
 Total RNA from cells was extracted by using either RNAeasy kit (Qiagen, Inc.) 
or eZNA RNA isolation kit (Omega Bio-tek, Inc.) as per manufacture’s protocol. To 
determine the concentration of RNA, the RNA was diluted in TE buffer (10 mM Tris-Cl, 
1 mM EDTA, pH 8.0) and quantified on a spectrophotometer by measuring the 
absorbance at 260 nm.  A total 1µg of RNA was used to synthesize cDNA by using 
TaqMan reverse transcription kit (Applied Biosystems, Inc.). The conditions used for 
cDNA synthesis are as follows; 10 minute at 25oC, 30 minute at 48oC and 5 minute at 
95oC. Quantitative Real-Time PCR analysis was performed in a 96 well micro titer plate 
format on a ABI Prism7900HT sequence detection system using TaqMan Universal 
master mix or TaqMan 2X master mix and gene specific Assays on Demand. Assays on 
Demand (AOD) used are VDR (Hs_0017213_m1), p21 (Hs_00355782_m1), p63 
(Hs_00978340_m1), IGFBP-3 (Hs_00426287_m1), CYP27B1 (Hs_ 00168017_m1), p73 
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(Hs_ 00232088_m1), Osteopontin (OPN) (Hs_ 00167093_m1), Osteocalcin (OCN) 
(Hs_01587813_m1), Runx2 (Hs_00231692), murine p63 (mm_00495788_m1), murine 
vdr (mm_00437297_m1) and murine id2 (mm_00711781_m1) (PE Applied Biosystems, 
Inc.). A total 40 ng of cDNA was used for a single PCR reaction and each cDNA sample 
was run in triplicates and GAPDH was used as endogenous control for normalizing the Ct 
values. Relative mRNA quantitation was performed by using the comparative ∆∆Ct 
method on SDS 2.0 software (Pfaffl, 2001) and error bars represent the standard 
deviation of RQ (relative quantification) values from triplicates.  
D. Western blot analysis 
 At appropriate times, cells were first washed in PBS and whole cell extracts were 
made using RIPA buffer (0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS, phosphate 
buffered saline, pH 7.4). Total protein concentrations were measured by using BCA 
protein detection method and bovine serum albumin (BSA) was used as a standard. Equal 
amounts of protein were mixed with appropriate amount of 5X SDS loading dye (0.5 M 
DTT, 0.3 M Tris (pH 6.8), 10% SDS, 50% glycerol and 0.05% bromophenol blue) to 
obtain 1X SDS loading dye containing protein samples. Subsequently, protein were run 
on a 10% SDS-PAGE gel and transferred onto PVDF membrane and blocked with 
blocking solution (5% non dry fat milk powder in TTBS (1X TBS, 0.1% Tween-20)). 
Membranes were subsequently probed with antibodies to detect specific proteins. 
Monoclonal anti-VDR, rabbit polyclonal anti-p21, monoclonal anti-p63 4A4 (Santa Cruz 
Biotechnology, Inc.) and monoclonal anti-β-actin (Sigma) antibodies were used to detect 
VDR, p21, p63 and β-actin expression respectively. Rabbit polyclonal anti-p73 antibody 
(Bethyl laboratories Inc., Montgomery, TX) was used to detect p73 expression. Mouse 
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monoclonal anti-p63 C-12 antibody was used for detecting exogenous ∆Np63α protien. 
Monoclonal anti-p53 Ab-6 (Calbiochem, San Diego, CA) was used to detect p53. 
Appropriate horseradish peroxidase-conjugated antibodies (Promega, Madison, WI) were 
used as secondary antibodies and Supersignal Westpico Chemiluminescent Substrate kit 
(Pierce, Inc.) was used to detect chemiluminescence signal on a FUJI FILM LAS3000 
image reader. 
E. Immunoprecipitation for endogenous p73 
 Cells were harvested for total protein using RIPA buffer and 1 mg of total protein 
was used for immunoprecipitation. Total protein was pre cleared with 20 µl of 
recombinant-protein G-Sepharose beads (Invitrogen, Inc.) for 1 hr at 4oC. After pre 
clearing beads were removed and the protein was incubated with rotation for O/N at 4oC 
with 1 µg of monoclonal anti-p73 antibody (Ab-4 Lab Vision Corporation). The next day 
pre-cleared protein samples were incubated with 25 µl of rec-protein G-Sepharose beads 
for an hour followed by 4X washes with RIPA buffer to remove the unbound proteins.  
Immunoprecipitated samples with beads were resuspended in appropriate 5X SDS 
loading dye (0.5 M DTT, 0.3 M Tris (pH 6.8), 10% SDS, 50% glycerol and 0.05% 
bromophenol blue) to obtain 1X SDS loading dye containing protein samples and were 
run on a 10% SDS PAGE gel. Subsequently, immunoblot analysis was performed with 
rabbit polyclonal anti-p73 antibody (Bethyl laboratories Inc.) and images were developed 
as explained above. 
F. Transactivation assays 
 Transactivation assays were performed by two different methods, single luciferase 
reporter assay method and dual luciferase assay method. For single luciferase reporter 
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based transactivation assay, cells were washed once with PBS and harvested in Single 
Lysis buffer (1XPBS, 0.15mM EDTA and 0.1% Triton-X 100). Luciferase reporter 
activity was measured by using Luciferase activity assay (Promega, Inc.) and Bradford 
assay (Bio Rad, Inc.) was performed to detect total protein concentration. Relative 
luciferase units were calculated by normalizing luciferase activity to total protein 
concentrations. For Dual luciferase assays, cells were transfected with desired firefly 
reporter construct and 5 ng of Renilla luciferase reporter construct (Promega, Inc.) along 
with desired plasmids. At 24 hr post transfection cells were washed once with PBS and 
harvested in passive lysis buffer (Promega, Inc.). Dual luciferase assay were performed to 
detect both firefly and Renilla luciferase activity using Dual-Luciferase Reporter 1000 
Assay System as per manufacturer’s protocol (Promega, Inc.). The relative luciferase 
activity (RLU) was measured by calculating ratio of Renilla luciferase activity to Firefly 
luciferase activity. The relative fold change in RLU activity was calculated by comparing 
to control vector transfected cells. The error bars represent the standard deviation from 
duplicate samples from same experiment.  
G. Chromatin Immunoprecipitation assays 
 Chromatin Immunoprecipitation assays (ChIP) were carried out using a ChIP kit 
(Active motif, Upstate Cell Signaling Solutions, Inc.). ChIP assay was performed either 
on H1299 cells transiently transfected with p63 or p53 and on normal H1299 or A431 
cells as required. For all purposes, three 15 cm dishes with cells at around 70-80% 
confluency were processed for ChIP assay. First cells were fixed on plate by using 10 % 
formaldehyde for 10 min. After fixation cells were scraped and cell pellet were 
resuspended in 1X lysis buffer. Subsequently cells were homogenized for 10 strokes 
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using a homogenizer and tight pestle. The homogenized cells were centrifuged to obtain 
nuclei and nuclei were resuspended in chromatin shearing buffer and subjected to 
sonication to shear the DNA. For the chromatin from H1299 cells overexpressed with 
p63 or p53, sonication was performed on Fisher scientific model 550 sonic dismembrator 
for total 8 cycles with 20-25 sec pulses for each cycle with 3 min resting time. For the 
chromatin from normal H1299 and normal A431 cells, sonication was performed on 
Fisher scientific model 500 sonic dismembrator for total 4 cycles each with 15 times of 5 
sec pulses with 15 sec off resting between each pulse. Sonicated chromatin was 
centrifuged at 14000 RPM for 12 min at 4 oC to obtain the fragmented chromatin. The 
fragmented chromatin in all the ChIP assays was in the size range of 400 bp to 600 bp.  
The fragmented chromatin was pre-cleared using protein G beads for 1.5 hrs and the pre-
cleared chromatin was subjected to overnight immunoprecipitation with appropriate 
primary antibodies. Part of pre-cleared chromatin (10%) which was not subjected to 
immunoprecipitation was used as input DNA. After immunoprecipitation both input 
DNA and immunoprecipitated chromatin were reverse cross linked at 65 oC for 16 hrs 
using 5M NaCl and DNA was eluted. The fragmented chromatin from H1299 cells 
overexpressed with p53 or p63 was immunoprecipitated with anti-p63 rabbit polyclonal 
(H-137), ant-p53 rabbit polyclonal (FL393) antibody and normal rabbit IgG antibodies 
(Santa Cruz Biotechnology Inc.). PCR amplification was performed by using Pfx 
polymerase (Invitrogen Inc.) with the following PCR conditions. For VDR, 38 cycles 
were performed each consisting of 30 sec at 940, 30 sec at 580 and 45 sec at 680 ; for 14-
3-3, 38 cycles were performed each consisting 30 sec at 940, 30 sec at 580 and 45 sec at 
680. Primers used for amplification are as follows: VDR, forward 5'-CGGGGTACCCAG 
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TAACAGGTTGCGACGGAG-3' and reverse 5'-
CCCAAGCTTGATGATTATAGGTGCG GATACCCG-3` For 14-3-3σ, forward 5'-
CTCACTACCTCAAGATACCC-3' and reverse 5'-CACAGGCCTGTGTCTCCC-3'.  To 
determine the occupancy of endogenous p73 protein on target genes fragmented 
chromatin from intact H1299 cells was immunoprecipitated with mouse mono clonal 
anti-p73 Ab-4 (Lab Vision Corporation) or normal rabbit IgG antibodies (Santa Cruz 
Biotechnology Inc. The eluted DNA was subjected to PCR amplification using GoTaq 
Green PCR master mix as per manufacture’s protocol (Promega, Madison, WI) using 
primers specific for VDR (forward 5'- CGGGGTACCCAG 
TAACAGGTTGCGACGGAG -3' and reverse 5'- 
CCCAAGCTTGATGATTATAGGTGCGGATACCCG -3') and p21 (forward 5'-
GGTACCGGCACTCTTGTTCCC CC AGGC TG-3' and reverse 5'-CTCGAGACCATC 
CCCTTCCTCACCTGAAAA-3'). PCR conditions used for both VDR and p21 are as 
follows, a total of 40 cycles were performed each consisting 30 sec at 940 C, 30 sec at 
600C and 45 sec at 680 C. To determine the binding of endogenous p63 protein on target 
genes, fragmented chromatin from intact A431 cells was immunoprecipitated with 
monoclonal anti-p63 4A4, rabbit polyclonal H-129 and normal mouse monoclonal IgG 
antibodies (Santa Cruz Biotechnology Inc.). Eluted DNA was subjected to PCR 
amplification for two regions (RE1 and RE2) within VDR promoter, p21 promoter and β-
actin gene using GoTaq Green PCR master mix (Promega, Madison, WI). Primers used 
for PCR amplification as follows VDR RE1 (forward 5'- 
CGGGGTACCTTTTCCGCAGCCATCCACA -3' and reverse 5'-
CCCAAGCTTCTGCAGAACGCCAGGAAGCTC-3'), VDR RE2 (forward 5'- 
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CGGGGTACCCAG TAACAGGTTGCGACGGAG -3' and reverse 5'- 
CCCAAGCTTGATGATTATAGGTGCGGATACCCG -3'), and p21 (forward 5'-
GGTACCGGCACTCTTGTTCCC CC AGGC TG-3' and reverse 5'-CTCGAGACCATC 
CCCTTCCTCACCTGAAAA-3'). The conditions used are as follows, a total of 38 cycles 
were performed each consisting 30 sec at 940 C, 30 sec at 600C and 45 sec at 680 C.  
H. siRNA transfections 
 Calcium phosphate based transfections were performed for transfecting siRNA 
oligo into A431, H1299 and SaOS2 cells. Cells were plated in 6 well plates prior to day 
of transfections and at around 30- 40 % confluency, cells were transfected with total 110 
pico moles of siRNA oligo. Total two rounds of siRNA transfections were carried out at 
24 and 48 hr post seeding. One hour before onset of siRNA transfections the medium on 
the cells was replaced with fresh medium and incubated in an incubator with 3% CO2. 
Following that transfection reaction mix was prepared by mixing siRNA with CaCl2 
(125mM final concentration) and 2X BBS (50mM BES (pH 7), 280mM NaCl, 1.5mM 
Na2HPO4). The transfection mixture was incubated for 3 minutes at room temperature 
and then added onto respective wells. After transfections, cells were kept back in 
incubator with 3% CO2. At 6 hr post transfections medium was replaced with fresh 
medium and cells were kept back in incubator with 5% CO2. All the siRNA used for 
studies were purchased from Qiagen (Qiagen, Valencia, CA) and the target Sequences 
used for siRNA are as follows, p63 siRNA 1 (CACCCTTATAGTCTAAGACTA), p63 
siRNA 2 (CCAGATGACATCCATCAAGAA), p73 siRNA1 
(CCCGGGATGCTCAACAACCAT), p73 siRNA2 
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(CTCGGGAGGGACTTCAACGAA) and VDR siRNA 
(CCGCGTCAGTGACGTGACCAA). 
I. Wound healing assays 
 For the wound healing assay A431 cells were transfected twice with desired 
siRNA as described earlier. At 24 hr post transfection a 200 µl pipette tip was used for 
creating an artificial wound or a cleared area on monolayer cells. Scratched cells were 
washed with 1X PBS and were re fed with fresh medium and allowed to grow for 24 hr. 
Immediately after the scratching (0 hr) and after 24 hrs, cell images were taken to 
visualize migrated cells and wound healing.  
J. Matrigel based invasion assay 
 The matrigel membrane based invasion assays were performed using 24 well BD 
BioCoat Matrigel Invasion chambers (BD Biosciences). The matrigel invasion chambers 
contain 8 micron pore size PET membrane with a layer of basement membrane made of 
matrigel. While the basement membrane blocks the migration of non-invading cells 
through the PET membrane, the invading cells can invade through the basement 
membrane and PET membrane, thus distinguishing the invading cells from non-invading 
cells. The control insert chambers lack the basement membrane and are used for ruling 
out any inconsistencies in cell seeding into the chambers. First, both invasion chambers 
and control inserts were placed in 24 well plates and were re-hydrated by adding 500 µl 
of serum free DMEM inside and outside of chambers. After medium was added onto 
chambers plates were incubated for 2 hrs at 37 oC in an incubator with 5% CO2. After 
chambers were re-hydrated, a total of 1×105 cells from each condition were resuspended 
in 500 µl of DMEM medium and seeded onto both invasion chambers and control inserts. 
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Fetal bovine serum was used as chemo-attractant and total 750 µl of medium containing 
FBS was added onto the lower part of invasion chambers. After cells were seeded onto 
chambers, plates were kept in an incubator with 37 oC and 5% CO2. After 24 hrs 
chambers were retrieved from the incubator and subjected to the staining process. First, 
the cells present inside the invasion chambers were removed using cotton swabs and the 
invaded cells present on the bottom of the lower membrane were stained with Diff-Quik 
stain kit. The Diff-Quik staining method involves staining the cells with three different 
staining solutions, solution I for fixing, solution II for cytoplasmic staining and solution 
III for nuclear staining. A total 500 µl of each solution was added in 24 well plates and 
cells were stained by sequentially incubating the chambers in each staining solution for 2 
mins. After cells were stained, chambers were air dried overnight. The next day, 
membranes were removed gently from chambers and were mounted on glass slides and 
dried for a day. Stained cell images were captured at 20X magnification using phase 
contrast microscopy and at least 9 images were captured from multiple fields. The 
number of cells from each field was counted to calculate the number of invading cells.  
K. Generation of A431 stable cells using lentiviral expression system. 
 The ∆Np63α cDNA containing lentiviral expression plasmid was constructed by 
amplifying the ∆Np63α cDNA sequence from ∆Np63α plasmid and then cloning it into 
modified pLentiV6 vector at BamHI and XhoI sites. The primers used for amplifying the 
∆Np63α cDNA as follows, sense 5’-GGAGGATCCATGTTGTACCTGGAAAACA-‘3 
and anti-sense 5’-AAACTCGAGTCACTCCCCCTCCCTTT-‘3. The modified pLentiV6 
vector contains additional restriction sites and was a generous gift from Dr. Thomas 
Brown. The pLentiV6-eGFP construct was a generous gift from Dr. Steven Berberich.. 
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To prepare the lentivirus expressing eGFP or ∆Np63α, 293FT cells were transfected with 
9 µg of lentiviral expression plasmids with 7 µg of lentiviral packaging mix using 
Lipofectamine 2000 (Invitrogen, Inc.). At 24 hr post transfections medium was replaced 
with fresh medium. After 48 hrs medium was collected and centrifuged to remove debris, 
then the lentiviral supernatant was collected and stored at -80 0C as 1 mL stocks. The 
A431-eGFP and A431-p63 stable cells were generated by infecting the parental A431 
cells with lentivirus expressing eGFP or ∆Np63α respectively. Briefly, prior to the day of 
infections A431 cells were seeded onto 6 well dishes. The next day lentiviral supernatant 
(1 mL) was thawed and was diluted in 500 µl medium containing polybrene (1.4 µg/mL). 
The medium on wells was removed and 1.5 ml of diluted lentiviral supernatant was 
added to appropriate wells. At 24 hr post infections lentivirus containing medium was 
replaced with fresh medium. After 24 hrs medium was replaced with fresh medium 
containing blasticidin (10 µg/mL) antibiotic to select the transduced cells. After 48 hrs 
cells were released from selection and as explained above another round of selections 
were carried out to obtain the final stable pool of A431 cells expressing ∆Np63α or 
eGFP. The stable expression of ∆Np63α  was confirmed by performing immunoblot 














A. TAp63γ up-regulates VDR expression in human cancer cell lines.  
   The role of p63 in epithelial morphogenesis and differentiation is well 
documented; however, the underlying p63 downstream signaling pathways that are 
responsible for p63 biology are still understudied. In an effort to identify such p63-
specific gene targets, our lab performed a microarray-based gene expression analysis 
using H1299 cells transiently transfected with TAp63γ. Extensive data mining analysis 
showed up-regulation of a significant number of genes by p63 and interestingly the 
vitamin D receptor (VDR) gene was observed in the list of genes upregulated by p63 
(data not shown). To determine whether VDR is specifically activated by TAp63γ, the 
gene chip results were validated by performing the transient transfection experiments. 
H1299 and HeLa cells were transfected with control vector, TAp63γ and p53 expression 
plasmids and at 24 hr post transfection cells were harvested for either total RNA or whole 
cell extracts. TaqMan based real time PCR was performed to detect the transcript levels 
of VDR and p21 and western blot analysis was performed to detect the endogenous VDR 
and p21 protein expression levels. Both p63 and p53 have been shown to activate p21 
expression and the detection of p21 expression was used as a positive control for both 








Figure 6: Induction of VDR expression by TAp63γ.  H1299 and HeLa cells were 
transfected with control vector, p63γ or p53 as indicated. At 24 hr post transfection, total 
RNA (A) or whole cell lysates (B) were extracted. A) TaqMan based Reverse 
transcriptase PCR was performed to quantitate the transcript levels of Vitamin D receptor 
(VDR) (upper panel) and p21 (lower panel) in H1299 (left) and HeLa (right) cell lines as 
indicated. Y-axis represents fold change in expression levels in p63γ and p53 transfected 
cells compared to empty vector transfected cells. B) Immunoblot analysis was performed 
to detect the endogenous VDR and p21 protein levels and also over expressed p63 and 







































Figure 7: Transactivation of VDR by TAp63γ.  H1299 (left) HeLa (right) cells were 
transfected with 250 ng of VDR-Luc reporter alone or with p63γ and p53 expression 
plasmids as indicated. At 24 hr post transfection cells were harvested and luciferase 
assays were performed on the whole cell extracts. Y axis represents relative luciferase 
units normalized to protein concentration. Over expression of p63 and p53 proteins was 













transcript and protein levels in both cell lines (Figure 6). While a significant increase in 
VDR transcript and protein levels was observed with exogenous TAp63γ, over 
expression of p53 did not result in up-regulation of VDR expression at transcript or 
protein level (Figure 6). To determine whether TAp63γ activates VDR transcriptionally, a 
VDR-Luc reporter was constructed by cloning reported 1500 bp VDR promoter region in 
pGL3-basic luciferase reporter vector. H1299 cells were transiently transfected with 
VDR-Luc reporter alone or with TAp63γ or p53 expression plasmids and the extracts 
from same samples were run on SDS-PAGE gel to confirm the overexpression of 
TAp63γ and p53 proteins (Figure 7). As shown in Figure 7, TAp63γ transfected cells 
showed a significant increase in VDR-Luc reporter activity when compared to the control 
vector transfected cells. Consistent with transcript and protein levels results, p53 was 
unable to induce VDR-Luc activity, suggesting VDR as a specific target of 
TAp63γ (Figure 7).  
 Given p53 was unable to activate VDR expression and that both p63 and p53 bind 
to the similar responsive elements, next we determined whether p53 affects the TAp63γ 
mediated induction of VDR. H1299 and HeLa cells were over expressed with p63 alone, 
p53 alone or together and expression of VDR and p21 were determined at the transcript 
and protein levels. Although p53 had no effect on the TAp63γ mediated activation of 
VDR, p53 by itself induced the expression levels of p21 at transcript and protein levels, 
suggesting that p53 does not affect VDR expression directly or indirectly (Figure 8). To 
further confirm the specificity of TAp63 mediated activation of VDR, studies were 
performed by inhibiting the TAp63 using the negative regulators of p63. Since, the p63γ 










Figure 8: p53 does not affect p63 mediated induction of VDR. H1299 and HeLa cells 
were transfected with empty vector, p63 γ (1.5 µg) or along with p53 (1.5µg) and p53 
alone (1.5µg) as indicated. (A) At 24 hr post-transfection, total RNA was harvested and 
subjected to TaqMan Reverse transcriptase PCR. Y-axis represents fold change in VDR 
and p21 transcript levels relative to empty vector transfected cells. (B) Immunoblot 
analysis was performed to detect the endogenous VDR and p21 protein levels and also 
over expressed p63 and p53 proteins. Immunoblotting for β-actin was performed to 
















Figure 9: Down regulation of WT p63 mediated induction of VDR by mutant p63. 
H1299 and HeLa cells were co-transfected WT p63γ (1.5 µg  (lane 2)) or along with 
p63γ (R279H) mutant (1.5µg (lane 3)) and mutant alone (1.5µg (lane 4)) as indicated. (A) 
TaqMan Reverse transcriptase PCR analysis was performed to detect expression levels of 
VDR (upper panel) and p21 (lower panel) as indicated. Y-axis represents fold change in 
VDR and p21 transcript levels relative to empty vector transfected cells (lane 1). (B) 
Immunoblot analysis performed to detect the endogenous VDR and p21 protein levels 


























Figure 10: Mutant p63 down regulates WT p63 mediated transactivation of VDR. 
H1299 (left) and HeLa (right) cells were transfected with 250 ng of VDR-Luc reporter 
alone (lane 1) or co-transfected with expression plasmids encoding WT 
p63γ (0.5 µg) (lane 2) or along with p63γ (R279H) mutant (0.5µg (lane 4) and 1.0 µg 
(lane 5) or mutant alone (lane 3) as indicated. Cells were harvested at 24 hr post-
transfection and luciferase assays were performed. Y axis represents relative luciferase 
units normalized to protein concentration. Immunoblot analysis was performed to 
confirm the over expression of WT p63γ and mutant p63γ (R279H) proteins using anti-


































towards wildtype (Celli et al., 1999; South et al., 2002;), the effect of  p63γ (R279H) 
mutant on wildtype (WT) p63 mediated activation of VDR was studied. Co-transfection 
of p63γ (R279H) along with WT TAp63γ led to a significant reduction in WT TAp63γ 
mediated induction of VDR and p21 at both transcript and protein levels (Figure 9). Co-
transfection of TAp63γ with increasing concentrations of p63γ (R279H) mutant resulted 
in a dose dependent down regulation of WT TAp63γ mediated transactivation of VDR-
Luc reporter activity (Figure 10). However, over expression of p63γ (R279H) mutant by 
itself had no effect on VDR expression at protein or transcript levels or on VDR-Luc 
activity (Figure 9 & 10).  
 Since the discovery of p63, numerous studies were centered on identifying the 
functional similarities and dissimilarities between p53 and p63. Particularly, studies were 
carried out to understand the effect of proteins that regulate p53 on p63 function.  
Recently, p63 mediated transactivation of its responsive genes was shown to be inhibited 
by p14ARF (Calabro et al., 2004).  Tumor suppressor p14ARF promote G1 cell cycle arrest 
by activating p53 signaling pathway.  Co-transfection of p14ARF along with TAp63γ in 
both H1299 and HeLa cells resulted in significant reduction in p63 mediated induction of 
VDR expression at both transcript and protein levels (Figure 11). Additionally, p14ARF 
inhibited TAp63γ mediated transactivation of VDR-Luc reporter activity in both H1299 
and HeLa cell lines (Figure 12). Co-transfection of p14ARF with TAp63γ also led to a 
significant inhibition in TAp63γ mediated activation of p21. As expected, exogenous 
p14ARF by itself had no effect on VDR expression at transcript or protein levels (Figure 
11). Thus inhibition of p63 mediated induction of VDR by both p14ARF and p63γ 










Figure 11. p14ARF inhibits TAp63γ mediated up-regulation of VDR. H1299 and HeLa 
cells were transfected with either empty vector, p63γ alone or along with p14ARF or 
p14ARF alone as indicated. (A) At 24 hr post-transfection, total RNA was extracted and 
subjected to TaqMan Reverse transcriptase PCR to quantitate VDR (upper panel) and 
p21(lower panel) transcript levels. Y-axis represents fold change in VDR and p21 
transcript levels relative to empty vector transfected cells (lane 1). (B) At 24 hr post-
transfection, total protein was extracted and immunoblot analysis was performed to detect 









































Figure 12. p14ARF down regulates TAp63γ mediated transactivation of VDR. H1299 
(left) HeLa (right) cells were transfected with 250 ng of VDR-Luc reporter alone or with 
p63γ alone or along with p14ARF or p14ARF alone as indicated. At 24 hr post-transfection 
cells were harvested and luciferase assays were performed. Y axis indicates the VDR 
promoter activity and represents relative luciferase units normalized to protein 
concentration. Immunoblot analysis was performed to confirm the over-expression of p63 






B. VDR is direct target of p63 and identification of p63 responsive element within 
VDR promoter. 
 Chromatin immunoprecipitation assay (ChIP) was performed to demonstrate that 
VDR is a direct target of p63. H1299 cells were transfected with either p53 or TAp63γ 
plasmids and at 24 hr post transfection cells were subjected to ChIP assay. The sonicated 
chromatin was immunoprecipitated with control IgG and p63 or IgG and p53 specific 
antibodies for cells over expressed with p63 or p53 respectively (Figure 13). DNA from 
the immunoprecipitated chromatin was then PCR amplified with primers specific for 
VDR and 14-3-3σ promoters. 14-3-3σ promoter amplification was used as a positive 
control for both p63 and p53 as both p63 and p53 are known to bind the 14-3-3σ 
promoter (Westfall et al., 2003). A substantial abundance of TAp63γ protein on a specific 
region within the VDR promoter was observed (Figure 13), but the occupancy of p53 
protein on the VDR promoter region was not observed. These results clearly demonstrate 
that VDR is direct transcriptional target of TAp63γ.  
 A recent report indicated that TAp63γ can induce genes by binding to both p63-
specific and p63/p53-specific consensus binding sites (Osada et al., 2005). Since VDR is 
up regulated only by TAp63γ but not by p53, studies were conducted to identify the p63 
specific responsive element within the VDR promoter. To delineate the p63 responsive 
element required for the induction of VDR by p63, a series of promoter deletion reporters 
were constructed. VDR promoter regions (-1267 to 1), (-1020 to 1), (-765 to 1) and (-631 
to -585) were cloned upstream of the pGL3 basic vector. The -631 to -585 region of the 
VDR promoter was specifically cloned as our in-silico based analysis indicated the 













Figure 13. TAp63γ binds to VDR promoter in vivo. H1299 cells were transfected with 
p63γ or p53 expression plasmids and at 24 hr post-transfection cells were subjected to 
Chromatin Immunoprecipitation analysis. Formaldehyde cross-linked chromatin was 
immunoprecipitated with anti-p63, anti-p53 or normal IgG antibodies as indicated. Eluted 

















Figure 14. Identification of p63 responsive element within the VDR promoter. The 
indicated regions within VDR promoter were constructed and transfected into H1299 
cells along with control vector or p63. At 24 hr post-transfection cells were harvested to 
subject for luciferase assays. Y axis represents relative luciferase units normalized to 
protein concentration. Lower Panel represents a schematic representation of the VDR 
promoter region containing the putative p63 binding elements.  The nucleotide sequences 


















































































Figure 15. TAp63γ promotes the differentiation of SaOS2 osteosarcoma cells. SaOS2 
cells were transfected with control vector, p63γ, p53 or p63γ(R279H) expression 
plasmids as indicated. At 48 hr post transfection morphological changes of cells were 
analyzed by phase contrast microscopy. For each condition images of cells were taken 
from six different fields randomly in unbiased manner. Percentage of differentiated cells 
(differentiated cells/total number of counted cells from several fields), as determined by 
morphological changes are indicated. The left panel graph represents the percent of 










cells were co-transfected with different VDR promoter deletion constructs along with 
either control vector or TAp63γ expression plasmids. The deletion of first 736 
nucleotides (-1500 to -765) from the transcription start site did not abolish the p63 
mediated increase in VDR-Luc activity (Figure 14). TAp63γ also significantly increased 
the VDR (-631 to -585) reporter activity which contains a potential p63 responsive 
element. These results suggest that VDR is direct target of p63 and that p63 stimulates 
the expression of VDR from a p63 responsive element within the VDR promoter.  
C. Exogenous TAp63γ  promotes differentiation by inducing VDR. 
 Vitamin D receptor has been shown to play major role in bone formation and 
osteoblastic differentiation. Therefore, studies were carried out to determine whether 
VDR induction by p63 promotes osteoblastic differentiation and whether p63 potentiates 
vitamin D-mediated osteoblastic differentiation. Osteosarcoma cell line SaOS2, a well 
studied model system for osteoblastic differentiation was employed for these studies. 
SaOS2 cells were transfected with a control vector, TAp63γ, p53 or TAp63γ (R279H) 
expression plasmids and morphological changes observed upon differentiation were 
monitored. The morphological features observed upon SaOS2 cells differentiation 
include elongated cytoplasmic processes and flattened fibroblastic appearances. A total of 
63% of the cells transfected with TAp63γ showed the differentiation morphology, 
whereas cells transfected with p53 or TAp63γ (R279H) mutant showed only 23% and 
12% of differentiation morphology respectively (Figure 15). p63 mediated induction of 
osteoblastic differentiation was further validated by monitoring the well studied 
differentiation markers osteopontin (OPN), RUNX2 and osteocalcin (OCN). In 











Figure 16. Induction of VDR and osteoblastic differentiation markers by p63 in 
SaOS2 cells.  SaOS2 cells were transfected with control vector or TAp63γ  or p53 or 
p63γ (R279H) mutant expression plasmids as indicated. After 48 hrs, transcript levels of 
VDR, OPN, OCN, RUNX2 and p21 were detected by performing TaqMan Reverse 
transcriptase PCR. Y-axis represents the relative fold change in expression levels in p63γ, 











Figure 17. TAp63γ enhances the vitamin D mediated differentiation of SaOS2 cells.  
SaOS2 cells were transfected with p63γ  or vector as indicated and at 24 hr post-
transfection, cells were either treated with control vehicle or with VD (100 nM). After 48 
hrs, TaqMan Reverse transcriptase PCR was performed to detect the transcript levels of 
OPN. Y-axis represents the relative fold change in OPN expression levels relative to 






a significant induction in OPN, OCN, RUNX2 and VDR transcript levels (Figure 16). 
Both p53 and p63γ (R279H) mutant were unable to induce the expression of OPN, OCN, 
RUNX2 and VDR (Figure 16). These results suggest that activation of VDR by p63 is 
involved in differentiation of SaOS2 osteosarcoma cells. To test whether exogenous p63 
potentiates vitamin D mediated differentiation, SaOS2 cells were transfected with either 
control vector or TAp63γ and transcript levels osteopontin were monitored in presence of 
vitamin D. Compared to vector transfected cells, cells transfected with TAp63γ showed 
an increase in vitamin D mediated increase in OPN transcript levels. These results 
suggest that p63 enhances the vitamin D mediated function by inducing the VDR 
expression levels (Figure 17). 
D. Transcriptional activation of VDR by all the isoforms of p63.  
 Having shown the transcriptional activation of VDR by TAp63γ, the regulation of 
VDR by all the isoforms of p63 was studied. This is important since the most abundant 
isoform of p63 expressed in basal epithelial cells of the skin is ∆Np63α and VDR is also 
shown to be expressed in basal and upper layers of differentiating skin (Cianferotti et al., 
2007). To determine the effect of different p63 isoforms on endogenous VDR expression, 
six different isoforms of p63 (TAp63γ, TAp63β, TAp63α, ∆Np63γ, ∆Np63β and 
∆Np63α,) were overexpressed in H1299 and HeLa cell lines and the expression of VDR 
at transcript and protein levels was monitored. As a positive control the transcript and 
protein levels of p21 were monitored as p21 was shown to be positively regulated by all 
the isoforms of p63 except ∆Np63α (Barbieri et al., 2005; Petitjean et al., 2008). A 
significant increase in VDR transcript levels were observed in cells transfected with all 











Figure 18. Up-regulation of VDR transcript levels by p63 isoforms. H1299 (A) and 
HeLa (B) cells were transfected with either empty vector, or expression plasmids 
encoding all the isoforms of p63 as indicated. TaqMan based Reverse transcriptase PCR 
was performed to detect the transcript levels of VDR and p21. Y-axis represents the 










Figure 19. Induction of VDR protein levels by p63 isoforms. H1299 (A) and HeLa (B) 
cells were transfected with either empty vector, or expression plasmids encoding all the 
isoforms of p63 as indicated. Western blot analysis was performed to determine the 




expected a significant increase in p21 transcript levels by TAp63γ, TAp63β and TAp63α, 
and ∆Np63β isoforms but not ∆Np63γ and ∆Np63α was observed. Consistent with 
transcript levels results, all the isoforms of p63 elevated the VDR protein levels. 
However, TAp63γ, TAp63β,  TAp63α and ∆Np63β  isoforms induced the VDR protein 
levels much higher than that of ∆Np63γ and ∆Np63α isoforms (Figure 19). Except the 
∆Np63α isoform, all the isoforms of p63 induced the p21 protein levels, albeit a modest 
increase by ∆Np63γ (Figure 19). These results clearly show that, all p63 isoforms 
including ∆Np63α can transcriptionally activate VDR. 
 A report indicated that ∆Np63α isoform exerts a dominant negative effect 
towards p53 and TAp63 isoforms (Senoo et al., 2001). Since the induction of VDR by 
both ∆Np63α and TAp63 isoforms was observed, the effect of ∆Np63α isoform on 
TAp63 mediated activation of VDR was examined. H1229 cells were transfected with 
TAp63γ alone or along with increasing concentrations of ∆Np63α and transcript levels of 
VDR, p21 and IGFBP-3 (Insulin growth factor binding protein-3) were monitored. 
Earlier reports have shown that, ∆Np63α  represses the expression of both p21 and 
IGFBP-3 (Barbieri et al., 2005; Westfall et al., 2003), therefore the expression of p21 and 
IGFBP-3 were used as controls for ∆Np63α mediated dominant negative effect on 
TAp63. As expected TAp63γ  but not ∆Np63α upregulated the transcript levels of both 
p21 and IGFBP-3. While ∆Np63α clearly downregulated TAp63 mediated induction of 
p21 and IGFBP-3, it had no affect TAp63γ mediated induction of VDR (Figure 20). 
Consistent with the transcript levels results, co-transfection of ∆Np63α did not lead to a 









Figure 20. ∆Np63α does not inhibit TAp63 mediated induction of VDR. A) H1299 
cells were transfected with either empty vector or TAp63γ alone or along with increasing 
concentrations of ∆Np63α as indicated. After 24 hrs TaqMan based real time PCR was 
performed to detect the transcript levels of VDR, p21 and IGFBP-3. Y-axis represents 
fold change in VDR, IGFBP-3 and p21 transcript levels relative to empty vector 
transfected cells. B) H1299 cells were transfected with either empty vector or TAp63γ 
alone or along with ∆Np63α or ∆Np63α alone as indicated. Immunoblot analysis was 































20). These results clearly demonstrate that ∆Np63α does not act in dominant negative 
manner towards TAp63 mediated induction of VDR in H1299 cells. 
E. VDR is a direct target of ∆Np63α. 
 Since VDR expression was induced by ∆Np63α, next we determined whether 
VDR is a direct target of ∆Np63α. First, the ability of ∆Np63α to transactivate full length 
VDR promoter was studied. Co-transfection of full length VDR promoter construct 
(VDR-Luc) along with increasing concentrations of ∆Np63α led to a dose dependant 
increase in VDR-Luc activity (Figure 21A). To unequivocally confirm that VDR is a 
direct target of ∆Np63α, ChIP assay was performed on intact A431 cells. Human 
epidermoid cancer cell line A431 was employed for ChIP assay, as detectable 
endogenous expression levels of both ∆Np63α and VDR are observed in these cells. 
ChIP assay was performed using two different antibodies against p63 (4A4 and H-127) to 
determine the occupancy of endogenous ∆Np63α protein on the VDR promoter. Since 
∆Np63α isoform is the only isoform observed in A431 cells, anti-p63 monoclonal 4A4 
antibody which detects all the isoforms of p63 and anti-p63 polyclonal H-129 antibody 
which detects only alpha isoforms of p63 were used. As shown in figure 21B, 
endogenous ∆Np63α protein bound to two different regions (RE1 and RE2) within VDR 
promoter region. Since the size of fragmented chromatin was around 500 bp and the 250 
bp RE1 and RE2 regions are right next each other, it is possible that ∆Np63α binds to the 
VDR promoter on a single region. ∆Np63α is known to transrepress p21 (Westfall et al., 
2003) and as expected the binding of ∆Np63α on the p21 promoter was observed.   
  Given, the occupancy of endogenous ∆Np63α on the VDR promoter, we 








Figure 21. ∆Np63α transactivates VDR and binds to VDR promoter in vivo. A) 
H1299 cells were co-transfected with full length VDR promoter construct along with 
either control vector or increasing concentrations of ∆Np63α as indicated. At 24 hr post 
transfection, cells were subjected to dual luciferase assay. Y-axis represents the fold 
change in relative luciferase units compared to empty vector transfected cells. B) A431 
cells were subjected to chromatin immunoprecipitation assay and crosslinked chromatin 
was immunoprecipitated using two different antibodies for p63 and control IgG as 
indicated. Eluted DNA was used for PCR amplification of two different regions within 
VDR promoter (RE1 and RE2) and amplification of p21 promoter was used as positive 


































Figure 22. Silencing ∆Np63α results in reduced expression of endogenous VDR in 
A431 cell. A) A431 cells were transfected with either control siRNA (siCon) or two 
different siRNA against p63 as indicated. At 48 hr post transfection, TaqMan based 
Reverse transcriptase PCR was performed to detect the transcript levels of VDR and p63. 
Y-axis represents the fold change in VDR and p63 transcript levels relative to control 
siRNA transfected cells. B) A431 cells were transfected with either control siRNA or two 
different siRNA against p63 or p73 siRNA as indicated. At 48 hr post transfections, 
whole cell lysates were made and were subjected to immunoblot analysis. The 
endogenous protein expression levels of VDR, p63 and p73 were detected using anti-























A431 cells were transfected with two different siRNA’s against p63 to silence the 
endogenous expression of ∆Np63α. Compared to control siRNA transfected cells, cells 
transfected with p63 siRNA_1 or p63 siRNA_2 showed a complete reduction in p63 
transcript and protein levels (Figure 22). Silencing endogenous ∆Np63α led to a 
complete abolishment in endogenous VDR expression at transcript and protein levels, 
indicating the requirement of endogenous ∆Np63α  for the basal expression of VDR 
(Figure 22). Eventhough VDR can be activated by multiple isoforms of p73 (Kommagani 
et al., 2007), down regulation of endogenous ∆Np73α in A431 cells did not result in 
reduction in endogenous VDR expression. These results indicate that VDR is a direct 
target of ∆Np63α and that ∆Np63α is essential for basal VDR expression. 
F. The role of VDR regulation by ∆Np63α in cell migration and invasiveness. 
 A recent report demonstrated that loss of p63 expression lead to an increase in 
invasiveness of squamous cell carcinoma cells including A431 cells (Higashikawa et al., 
2007). Since silencing p63 led to a down regulation in VDR expression and vitamin D is 
shown to regulate genes involved in metastasis (Tokar and Webber, 2005), the role of 
∆Np63α mediated regulation of VDR in inhibition of invasiveness was determined. A431 
cells were silenced for either p63 or VDR and cell migration and cell invasion were 
assessed by wound healing and matrigel based assays, respectively. As shown in Figure 
23A & B, silencing either p63 or VDR in A431 cells led to an increase in wound closure, 
compared to control siRNA transfected cells, indicating enhanced cell migration. The 
matrigel membrane based invasion assays accurately measures the invasiveness and 
migration of cancer cell lines. Interestingly, knockdown of either p63 or VDR resulted in 







Figure 23. Down regulation of p63 or VDR results in increased cell migration and 
cell invasion in A431 cells. A431 cells were transfected with either control siRNA or 
p63 siRNA or VDR siRNA as indicated. A) After 24 hrs cells were initiated for wound 
healing assay and microscopic pictures were taken at 0 hr and 24 hr post initiation of 
wound healing assay. B) The extent of wound closure after 24 hr was measured and 
normalized to 100% at 0 hr. Y-axis represents the percent in wound closure compared to 
0 hr and error bars represents the standard deviation from two independent experiments. 
C) Cells were subjected to matrigel based invasion assay as explained in methods section. 
After 24 hrs micrographic pictures of cells migrated through transwell membranes were 
taken and total number cells migrated through membranes were counted. Y-axis 
represents the number of cells invaded through membrane in p63 or VDR siRNA 
transfected cells compared to control siRNA transfected cells and error bars represent the 
standard deviation from two independent experiments. D) Immunoblot analysis was 

















Since the loss of either VDR or p63 results in enhanced invasiveness, we next tested 
whether induction of VDR by ectopic p63 results in diminished invasiveness. A431 cells 
stably expressing p63 or control eGFP were established and as expected, compared to 
A431 eGFP stable pool cells, a significant increase in both p63 and VDR expression 
levels were observed in A431-p63 stable pool cells (Figure 24A). Compared to A431-
eGFP stable pool cells, a significant reduction in number of invading cells was observed 
in A431-p63 stable pool cells, indicating that overexpression of p63 and VDR abrogates 
the normal invasion of A431 cells (Figure 24A). Additionally, to demonstrate that p63 
mediated inhibition of cell invasiveness occurs via VDR, the control A431-eGFP and 
A431-p63 stable pool cells were transfected with control siRNA or p63 siRNA and 
matrigel based invasion assays were performed. Since the p63 siRNA used for these 
studies targets the 3’UTR of p63 mRNA, the A431-p63 stable cells expressing only the 
coding region of p63 will not be silenced, therefore detectable expression of VDR can be 
observed even in absence of p63 (Figure 24B, right panel compare lane 2 and 4). 
Compared to control siRNA transfected cells, silencing p63 led to an increase in number 
of invading cells only in A431-eGFP cells but not in A431-p63 stable cells (Figure 24B). 
These results provide evidence that p63 mediated regulation of VDR play a role in 
inhibiting the migration and invasiveness of A431 cells.  
G. Significance of VDR regulation by p63 during embryonic development. 
 The functional roles of p63 and VDR in epidermal development are well 
established, VDR has been shown to induce terminal epidermal differentiation markers 
and VDR null mice had severe alopecia conditions (Xie et al., 2002). To determine the 





Figure 24. Re-expression of p63 and VDR results in reduced cell migration and cell 
invasion of A431 cells. A) A431-eGFP and A431-∆Np63α stable pool cells were 
subjected to matrigel based invasion assay (right panel). Y-axis represent the fold change 
in number of A431-∆Np63α stable pool cells invaded, compared to A431-eGFP stable 
pool cells. Immunoblot analysis was performed to detect the expression of ∆Np63α and 
VDR in both A431-eGFP and A431-∆Np63α stable pool cells (left panel). B & C) A431-
eGFP and A431-∆Np63α stable pool cells were transfected with either control siRNA or 
p63 siRNA as indicated. 24 hr post siRNA transfections cells were subjected to Matrigel 
based invasion assay (right panel). After 24 hrs cell images were taken from multiple 
fields and the invading cells were counted.  B) Y-axis represent the fold change in 
number of cells invaded compared to control siRNA transfected A431-eGFP cells and 
error bars represent the standard deviation from two independent experiments. 
Immunoblot analysis was performed to detect the expression of ∆Np63α and VDR in 
both A431-eGFP and A431-∆Np63α stable pool cells transfected with control siRNA or 
p63 siRNA as indicated (left panel). C) Representative cell images from A431-eGFP and 
A431-∆Np63α stable pool cells that were transfected with either control siRNA or p63 














Figure 25- p63 is essential for VDR expression during embryonic development. 
Total RNA from 18.5 embryonic day wild type MEFs and p63-/- MEFs were extracted 
and transcript levels of p63, VDR and Id2 were determined by using TaqMan based real 
time PCR analysis. Y-axis represents fold change in VDR, Id2 and p63 transcript levels 





























levels of both p63 and VDR were assessed in mouse embryonic fibroblast (MEF) from 
both wildtype and p63 null mice. Compared with wildtype MEF’s a significant reduction 
in VDR transcript levels were observed in p63 null MEF’s (Figure 25). Histochemical 
analysis of new born (NB), postnatal day 4 (P4) and day 16 (P16) wildtype mice skin 
showed the similar VDR and p63 expression pattern and the single layered skin of p63 
null mice showed a complete lack in VDR expression (data not shown (obtained by Dr. 
Satrajit Sinha)). Since the p63 mutations are observed in developmental diseases, the 
effect of several naturally occurring p63 mutants on VDR expression was determined. As 
shown in figure 26, a differential effect of p63 mutants on VDR expression was 
observed; while TAp63γ (R227C) and TAp63γ (R298Q) mutants were able to induce the 
VDR expression, all other tested mutants showed no effect on VDR expression.  
H. DNA damage induced expression of VDR is independent of p53 and correlates 
with p73 expression. 
 The results from our earlier studies clearly demonstrated that p63, but not p53, 
induces VDR expression (Kommagani et al., 2006). Recently, Maruyama et. al. (2006) 
demonstrated that p53 induces VDR expression and that VDR expression was induced 
upon DNA damage in p53 positive cell lines (Maruyama et al., 2006). One possible 
explanation for this discrepancy could be the differences in the amount of p53 employed 
for the over expression studies. Towards understanding the possible dose dependent 
effect of p53 on VDR expression, studies were carried out to test the effect of increasing 
concentrations of p53 on endogenous VDR expression. H1299 and HeLa cells were over 
expressed with increasing concentrations of p53 alone or p63 alone and transcript and 










































































































Figure 26.  Differential effect of naturally occurring p63 mutants on VDR. H1299 
cells were transfected with either empty vector or expression plasmids encoding WT p63 
or indicated p63 mutants alone. At 24 hr post-transfection, total RNA was extracted and 
subjected to TaqMan Reverse transcriptase to detect the VDR transcript levels. Y-axis 









Figure 27.  p53 does not induce VDR expression. H1299 and HeLa cells were 
transfected with either empty vector, increasing doses of expression plasmids encoding 
p53 (1 µg, 2 µg and 3 µg) and p63 alone (3 µg) as indicated. A) At 24 hr post-
transfection, total RNA was harvested and subjected to TaqMan reverse transcriptase 
PCR. Y-axis represents fold change in VDR and p21 mRNA levels relative to empty 
vector transfected cells. B) Whole cell lysates were subjected to immunoblot analysis to 

























 positive control for the transactivation of both p53 and p63. As seen earlier, exogenous 
p63 up-regulated the expression of both VDR and p21 at transcript and protein levels 
(Figure 27). In contrast, over expression of p53 at any tested dose did not result in 
induction of VDR at transcript or protein levels in both the cell lines (Figure 27). As 
expected, p21 was significantly induced by p53 at all the tested doses, thus confirming 
the transactivation potential of p53. Further, similar studies were performed to test the 
ability of p53 to transactivate VDR promoter using VDR-Luc reporter. Consistent with 
protein and transcript results, ectopic p53 had no effect on VDR-Luc reporter activity 
(data not shown).   
 Since ectopic p53 was unable to induce VDR expression in p53-/- cell lines 
(H1299 and HeLa), studies were carried out to determine whether DNA damage induced 
expression of VDR is dependent or independent of p53. H1299 and SaOS2 cells were 
examined for the effects of two DNA damaging agents, doxorubicin and etoposide, on 
VDR expression. An in depth multiple dose analysis was conducted prior to choosing 
appropriate doses for doxorubicin (0.2 µM and 0.4 µM) and etoposide (6 µM, 8 µM for 
H1299 and 2 µM, 4 µM for SaOS2). At 24 hr post etoposide and doxorubicin treatments 
transcript levels of VDR and CYP27B1 were measured by performing TaqMan based 
real time PCR. Measuring the transcript levels of CYP27B1, a known down stream target 
of VDR, was used as a positive control for VDR mediated induction of its target genes. In 
both cell lines, compared with untreated cells, a significant increase in VDR and 
CYP27B1 transcript levels were observed with etoposide and doxorubicin treatments 
(Figure 28), which suggests that transcriptional activation of VDR upon DNA damage 





     
 
 
Figure 28.  DNA damage induced expression of VDR is independent of p53. H1299 
and SaOS2 cells were either untreated or treated with Doxorubicin (0.2 µM and 0.4 µM) 
or Etoposide (6 µM, 8 µM for H1299 and 2 µM, 4 µM for SaOS2). After 24 hr TaqMan 
real time PCR was performed to determine the transcript levels of VDR, CYP27B1 and 











Figure 29.  Induction of VDR expression upon DNA damage correlates with p73 
expression and p73 up-regulation precedes VDR expression upon DNA damage. A) 
H1299 cells were either untreated or treated with doxorubicin or etoposide for 24 hr 
following which immunoblot analysis was performed to detect the protein levels of VDR 
and p73. For the detection of p73 protein levels whole cell lysates were first 
immunoprecipitated with monoclonal anti-p73 antibody and immunoblotted with 
polyclonal anti-p73 antibody. B) H1299 cells were treated with 8 µM etoposide and total 
RNA was extracted at indicated post-treatment time points. TaqMan based reverse 
transcriptase PCR was performed to detect the transcript levels of p73 and VDR. Y-axis 
represents the fold change in VDR and p73 transcript levels relative to untreated cells at 























Previous reports demonstrated that both these cell lines have endogenous p73, and p73 is 
induced upon DNA damage in various cancer cell lines (Chen et al., 2001; Urist et al., 
2004), therefore, the correlation between p73 and VDR expression levels upon DNA 
damage was studied. A considerable correlation between p73 and VDR transcript levels 
were observed with etoposide and doxorubicin treatment in both cell lines (Figure 28). 
Consistent with the transcript levels, endogenous protein levels of both VDR and p73 
were also significantly up-regulated upon etoposide and doxorubicin treatments in H1299 
cells (Figure 29A). Given the correlation between p73 and VDR expression levels upon 
DNA damage, we tested whether p73 induction precedes the VDR induction upon DNA 
damage. H1299 cells were treated with 8 µM etoposide then at 4, 6 and 16 hr post 
treatment transcript levels of VDR and p73 were measured. A significant increase in p73 
transcript levels were observed at 4 hr post etoposide treatment and VDR induction was 
observed only at 8 hr post etoposide treatment (Figure 29B), suggesting that p73 
induction precedes VDR induction upon DNA damage. 
I. Direct transcriptional regulation of VDR by p73. 
 To determine the possible direct transcriptional activation of VDR by p73, studies 
were carried out to determine whether p73 activates VDR and whether basal VDR 
expression levels are regulated by p73. To address this, the transcriptional activation of 
VDR by multiple p73 isoforms was determined. H1299 cells were transfected with 
different p73 isoforms or TAp63γ alone and the expression of VDR and p21 at transcript 
and protein levels were determined. TAp63γ was used as a positive control for both VDR 
and p21 induction. Over expression of TAp73β and TAp73α in H1299 cells led to a 







Figure 30.  Multiple isoforms of p73 up regulates VDR expression.  H1299 cells were 
transfected with control vector, TAp63γ, TAp73β, ∆Np73β, or TAp73α as indicated. A) 
At 24 hr post transfection, transcript levels of VDR and p21 were determined by Real 
time PCR and Y-axis represents the fold change in transcript levels of VDR and p21 
compared to empty vector transfected cells.  B) At 24 hr post-transfection, immunoblot 
analysis was performed to detect the endogenous VDR and p21 protein levels and to 
detect the ectopic expression of p63 and p73 isoforms. C) H1299 cells were co-
transfected with full length VDR promoter reporter along with indicated plasmids. At 24 
hr post transfection, cells were subjected to dual luciferase assays. RLU/R-Luc ratios 
were calculated to normalize for transfection efficiency. Y-axis represents fold change 




















Figure 31.  Endogenous p73 is essential for basal VDR expression and binds to VDR 
promoter in vivo.  A) H1299 cells were transfected with either control siRNA or p73 
siRNA and at 48 hr post transfection, Real time PCR was performed to detect the 
transcript levels of p73, VDR and CYP27B1. Y-axis represents fold change in transcript 
levels of VDR, CYP27B1 and p73 compared to control siRNA transfected cells. B) ChIP 
analysis on H1299 cells. Formaldehyde cross-linked chromatin was immunoprecipitated 
with anti-p73 or normal IgG antibodies as indicated. Eluted DNA was PCR amplified 
with primers specific for VDR and p21.  
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(Figure 30 A & B).  In contrast, ∆Np73β led to a modest increase in both VDR and p21 
expression levels when compared to the other TAp73 isoforms (Figure 30A & B).  Next 
the ability of different p73 isoforms in transactivating full length VDR promoter was 
tested. As expected, both TAp73β and TAp73α isoforms significantly increased the 
VDR-Luc reporter activity (Figure 30C).  
 Additionally, we determined whether endogenous p73 binds to the VDR promoter 
and controls the basal VDR expression levels. To test this, endogenous p73 was silenced 
in H1299 cells and VDR and CYP27B1 transcript levels were monitored. As shown in 
Figure 31A, compared with control siRNA, 80% reduction in p73 transcript levels were 
observed with p73 siRNA. Silencing p73 led to a concomitant decrease in the basal 
transcript levels of VDR as well as CYP27B1 (Figure 31A). Finally, ChIP analysis on 
intact H1299 cells demonstrated that p73 binds onto the VDR promoter in vivo. A 
significant abundance of endogenous p73 protein was observed on the VDR and p21 
promoters (Figure 31B). These results clearly suggest that VDR is transcriptionally 
activated by p73 and that endogenous p73 is essential for basal VDR expression in 
H1299 cells. 
J. p73 is required for DNA damage induced expression of VDR. 
 The requirement of p73 for the induction of VDR upon DNA damage was 
determined by either inhibiting the transcriptional activity of p73 or by silencing p73 in 
presence of DNA damage. To demonstrate that the transcriptional activity of p73 is 
required for VDR induction upon DNA damage, a dominant negative p53 (R248W) 
mutant shown to inhibit the transcriptional activity of p73 was employed. Since 








Figure 32.  Mutant p53 but not WT p53 inhibits p73 mediated induction of VDR 
upon DNA damage. A) H1299 cells were transfected with control vector or expression 
plasmids encoding TAp73α, WT p53 and p53 (R248W) mutant alone or in combination 
as indicated. Immunoblot analysis was performed to detect the endogenous VDR and p21 
protein levels and over expressed p73 and p53 proteins. B) H1299 cells were transfected 
with empty vector or p53 (R248W) or WT p53 as indicated. Next day cells were either 
untreated or treated with 8 µM etoposide as indicated. Immunoblot analysis was 
performed to detect the endogenous VDR protein levels and to confirm the over 
expression of WT and mutant p53. p73 protein levels were detected by performing 
immunoprecipitation with monoclonal anti-p73 antibody and immunoblotted with 












                          














Figure 33.  p73 is required for DNA damage induced expression of VDR. H1299 cells 
were transfected with control siRNA, VDR siRNA, or p73 siRNA and after 24 hr post 
transfections cells were trypsinised and re-plated onto 6 well plates. After cells adhered 
properly in wells, cells were treated with 8 µM etoposide or left untreated for 24 hrs. A) 
TaqMan real time PCR was performed to detect the mRNA levels of p73 and VDR. Y-
axis represents the fold change in transcript levels of VDR and p73 compared to control 
siRNA transfected cells with control vehicle (UT).B) Immunoblot analysis was 
performed to detect the endogenous VDR and p73 protein levels. p73 protein levels were 
detected by performing immunoprecipitation with monoclonal anti-p73 antibody and 
















VDR induction by ectopic TAp73α  was determined. As shown in Figure 32A, p53 
(R248W) mutant modestly down regulated TAp73α mediated induction of VDR. 
Consistent with previous observation that wild type p53 cannot inhibit p73 mediated 
transcriptional activity (Di Como et al., 1999), wild type p53 by itself did not affect 
TAp73α mediated  induction of VDR (Figure 32A). Further, blocking the endogenous 
TAp73 transcriptional activity by p53 (R248W) mutant but not wild type p53 
significantly down regulated the etoposide induced VDR protein expression levels 
(Figure 32B).  To unequivocally demonstrate that p73 is essential for VDR expression 
upon DNA damage, VDR induction upon DNA damage was assessed in presence and 
absence of p73. As shown in Figure 33, in control siRNA transfected cells, compared 
with untreated cells, etoposide treated cells showed a significant induction in both p73 
and VDR transcript and protein levels. However, in presence of p73 siRNA a significant 
inhibition of both basal and etoposide induced transcript and protein levels of p73 were 
observed. Concomitant decreases in elevated levels of VDR with etoposide were also 
observed in the presence of p73 siRNA, suggesting the requirement of p73 for DNA 
damage induced VDR expression (Figure 33). Overall, results from these studies 
demonstrate a novel p73 dependant induction of VDR in p53 null cell lines. 
K. DNA damage induced VDR expression sensitizes the cells to vitamin D treatment 
through p73.  
 Given that vitamin D exerts its transcriptional activity through VDR, endogenous 
p73 must be essential for vitamin D-mediated transcriptional activity. In addition, p73 
mediated induction of VDR upon DNA damage should further enhance the vitamin D-














Figure 34. Schematic representation of experimental design for Figure 35. Flowchart 
representing the experimental design to determine the effect of p73 silencing on vitamin 





Figure 35. p73 is required for DNA damage mediated enhancement of vitamin D 
transcriptional activity. A) H1299 cells were transfected with control vector or p63 
alone or along with shVDR or shNSC as indicated. At 24 hr post transfection cells were 
harvested for whole cell lysates and subjected to immunoblot analysis to detect VDR, p63 
and β-actin using specific antibodies.  B) H1299 cells were plated on 12 well plates and 
co-transfected with VDRE-Luc reporter along with either shNSC or shVDR as indicated. 
Next day cells were either treated with 8 µM etoposide or left untreated as indicated. 
After 12 hr of post treatment cells were treated with 100 nM VD as indicated. At 24 hr 
post VD treatment cells were subjected to dual luciferase assay. Y-axis represents the 
ratio of firefly luciferase units to renilla luciferase units. C) H1299 cells were transfected 
with control siRNA or p73 siRNA and after two rounds of transfections with siRNA cells 
were re-plated onto 24 well plates and reverse transfections were performed with VDRE-
Luc reporter. Next day cells were either treated with 8 µM etoposide or left untreated as 
indicated. Subsequently cells were treated with 100 nM VD as indicated. At 24 hr post 
VD treatment cells were subjected to dual luciferase assay as mentioned earlier. Y-axis 
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elevated levels of VDR observed upon DNA damage enhances the vitamin D-mediated 
transcriptional activity using short hairpin VDR construct (shVDR). A vitamin D 
responsive reporter, VDRE-Luc which bears two VDR responsive elements upstream of 
luciferase gene was used to monitor the vitamin D-mediated transcriptional activity. 
Silencing of VDR was achieved by using a short hairpin RNA (shRNA) specific to VDR 
(shVDR) and non-silencing control shRNA (shNSC) was used as a negative control. To 
confirm the effective silencing of VDR by shVDR, H1299 cells were transfected with 
expression plasmid encoding TAp63γ along with shVDR or non-silencing control. The 
increase in VDR levels induced by TAp63γ were abolished by shVDR but not by shNSC, 
confirming the specificity of the shVDR (Figure 35A). H1299 cells were co-transfected 
with VDRE-Luc reporter along with either shNSC or shVDR and subsequently cells were 
treated with etoposide, followed by 24 hr incubation in vitamin D. After 24 hrs, cells 
were harvested and VDRE-Luc activity was measured. Compared with control vehicle 
(UT), a significant increase in VDRE-Luc activity was observed with vitamin D 
treatment (Figure 35B). As expected, etoposide enhanced the increase in vitamin D-
mediated VDRE-Luc activity (Figure 35B). The increase in VDRE-Luc activity observed 
with vitamin D in presence and absence of etoposide was completely abolished in the 
absence of VDR, indicating that elevated VDR levels upon DNA damage enhance 
vitamin D mediated transcriptional activity (Figure 35B). 
 Next, to address whether p73 is required for DNA damage mediated enhancement 
of vitamin D transcriptional activity, a similar experiment was carried out by silencing 
p73 in H1299 cells as illustrated in Figure 34. As shown earlier, etoposide significantly 








Figure 36.  Silencing p73 results in reduction in vitamin D mediated transcriptional 
activity in SaOS2 cells. A) SaOS2 cells, mock transfected or transfected with two rounds 
of control siRNA or p73 siRNAs and after 48 hrs VDR and p73 transcript levels were 
determined. Y-axis represents the fold change in transcript levels of VDR, OCN and p73 
compared to control siRNA transfected cells. B) SaOS2 cells transfected with either 
control siRNA or p73 siRNA were transfected with VDRE-Luc construct along with 
Renilla luciferase construct. Dual luciferase assays were performed to detect the VDRE-
Luc activity and Y-axis represents the fold change in VDRE-Luc activity compared to 




































dramatic reduction in VDRE-Luc activity that was observed with etoposide and vitamin 
D together (Figure 35C). In addition, depletion of p73 also resulted in reduced basal 
vitamin D-mediated transcriptional activity (Figure 35C). These results clearly 
demonstrate the requirement of p73 for vitamin D-mediated transcriptional activity in 
presence and absence of DNA damage. 
L. p73 is required for vitamin D mediated osteoblastic differentiation. 
 To investigate the role of p73 in vitamin D mediated differentiation, we first 
tested whether endogenous p73 is essential for the basal VDR expression of SaOS2 cells, 
a well studied model system for vitamin D mediated osteoblastic differentiation. SaOS2 
cells were transfected with either control siRNA or two different p73 siRNA (siRNA 
p73_1 or siRNA p73_2). At 48 hr post transfections, real time PCR was performed to 
determine the transcript levels of p73 and VDR. Since vitamin D promotes the terminal 
differentiation, the detection of terminal osteoblastic differentiation marker OCN was 
used as a control for VDR down stream target. Compared to control siRNA transfected 
cells, cells transfected with siRNA p73_1 showed a considerable reduction in both p73 
and VDR transcript levels (Figure 36A). However, compared to control siRNA 
transfected cells, cells transfected with siRNA p73_2 showed a modest reduction in VDR 
transcript levels. In addition, a substantial down regulation in OCN transcript levels was 
also observed with both p73 siRNA_1 and p73 siRNA_2. Although both siRNA’s against 
p73 reduced the basal p73 expression levels, siRNA p73 _1 was more potent than siRNA 
p73_2, and thus p73 siRNA_1 was employed for subsequent studies. Consistent with the 
reduction in VDR transcript levels, compared to control siRNA transfected cells, a 














Figure 37.  Effect of vitamin D on p73 expression in SaOS2 cells. SaOS2 cells were 
treated with either vehicle (UT) or increasing concentrations of vitamin (VD) as 
indicated. At 48 hr post-treatment, total RNA was extracted and TaqMan based real time 
PCR was performed to detect the transcript levels of p73 and OPN and OCN. Y-axis 
























Figure 38. p73 is required for vitamin D mediated differentiation of SaOS2 cells. A) 
SaOS2 cells transfected with control siRNA or p73 siRNA were harvested and re-plated 
onto 6 well plates. Next day, cells were treated for 48 hr with vehicle or 10 nM or 100 
nM VD and total RNA was extracted and transcript levels of p73, VDR, OPN and OCN 
were determined. Y-axis represents the fold change in transcript levels compared to 
control siRNA transfected cells with vehicle treatment (UT). B) SaOS2 cells transfected 
with control siRNA or p73 siRNA were split and re-plated onto 6 wells. Next day, cells 
were treated with vehicle or 10 nM VD as indicated and at 48 hr post VD treatment 






















                     
                 
 
      
 105
cells in immunofluorescence (IF) assay (data not shown). Since, vitamin D mediated 
genomic actions are exclusively dependant on its receptor VDR, the effect of p73 
silencing on vitamin D mediated transcriptional activity in SaOS2 cells was determined. 
This was determined by monitoring the vitamin D mediated increase in VDRE-Luc 
reporter activity in presence and absence of p73. As expected, a significant increase in the 
VDRE-Luc activity was observed in cells transfected with control siRNA and treated 
with vitamin D (Figure 36B). However, silencing p73 lead to a significant reduction in 
vitamin D mediated VDRE-Luc activity (Figure 36B). 
 Since vitamin D and VDR primarily promote osteoblastic differentiation and p73 
knockdown also led to a decrease in basal VDR expression levels in osteosarcoma cells, 
next the effect of p73 silencing on vitamin D mediated osteoblastic differentiation was 
investigated. To investigate this, studies were conducted first to determine whether 
vitamin D by itself has any effect on endogenous p73 expression in SaOS2 cells. SaOS2 
cells were treated with increasing concentrations of vitamin D (10 nM, 25 nM, 50 nM, 
and 100 nM) for 48 hours, and the transcript levels of p73, OCN and OPN were 
examined. Since vitamin D mediated osteoblastic differentiation is associated with the 
induction of OPN and OCN expression, detection of OCN and OPN transcript levels 
were used as a positive control for vitamin D mediated genomic effect. As expected, a 
dose dependant induction in both OCN and OPN transcript levels were observed with 
increasing concentrations of vitamin D (Figure 37). However, vitamin D had no effect on 
p73 transcript levels at any of the tested doses, indicating that p73 is not regulated by 
vitamin D in osteosarcoma cells (Figure 37A). Next, to examine whether p73 is essential 







Figure 39. Effect of different p73 siRNA on vitamin D mediated induction of OCN. 
SaOS2 cells transfected with control siRNA or p73 siRNA 1 & 2 were harvested and re-
plated onto 6 well plates. Next day, cells were treated with vehicle (UT) or 10 nM VD 
and total RNA was extracted. After 48 hrs transcript levels of p73 and VDR (A) and 
OCN (B) were determined. Y-axis represents the fold change in transcript levels 







was monitored in SaOS2 cells treated from vitamin D in presence and absence of p73. As 
expected, p73 knockdown led to a significant decrease in p73 as well as VDR transcript 
levels (Figure 38A). A significant increase in OCN and OPN expression levels was 
observed in cells transfected with control siRNA and treated with vitamin D for 48 hrs, 
indicating the onset of differentiation in SaOS2 cells (Figure 38). p73 silencing however, 
led to a significant reduction in the elevated expression levels of OCN and OPN that were 
observed with vitamin D (Figure 38A).   
 In addition, morphological changes in cells observed upon differentiation were 
also monitored from cells treated with vitamin D in presence and absence of p73. In 
control siRNA transfected cells, compared to control vehicle a significant number of cells 
with differentiation morphology features were observed with vitamin D treatment (Figure 
38B, marked by an arrow). However, silencing p73 led to a significant reduction in 
number of cells with differentiation features that were observed with vitamin D treatment 
(Figure 38B).  
 To validate the role of p73 in vitamin D mediated differentiation, next the effect 
of two different siRNA against p73 on vitamin D mediated differentiation was carried 
out.  Testing two different siRNA against p73 will also address the off target effects of 
p73 siRNA during vitamin D mediated differentiation. SaOS2 cells were transfected with 
two different siRNA against p73 and vitamin D mediated osteoblastic differentiation was 
monitored by detecting the OCN expression. As shown in Figure 39, cells treated with 
vitamin D showed a increase in OCN transcript levels, however both the siRNA against 
p73 down regulated the OCN transcript levels that were observed with vitamin D 










Figure 40. DNA damage enhances vitamin D mediated differentiation of SaOS2 
cells. SaOS2 cells were pretreated for 24 hrs with 4 µM etoposide or 4 µM doxorubicin 
and subsequently cultured with vehicle or 10 nM VD for an additional 48 hrs. Total RNA 
was extracted and transcript levels of VDR, OPN (top panel) and p73, OCN (lower panel) 
were determined by TaqMan based real time PCR. Y-axis represents the fold change in 















to p73 siRNA_1, a modest decrease on OCN transcript levels was observed with p73 
siRNA_2.  Together these results clearly indicate that p73 is required for vitamin D 
mediated differentiation of SaOS2 osteosarcoma cell lines.  
M. DNA damage induced enhancement of vitamin D mediated osteoblastic 
differentiation requires p73. 
 To test whether p73 mediated induction of VDR expression upon DNA damage 
enhances the vitamin D mediated differentiation of SaOS2 cells, the effect of DNA 
damage on vitamin D mediated induction of OPN and OCN was determined. SaOS2 cells 
were pretreated with etoposide or doxorubicin for 24 hr and then were cultured in vitamin 
D for 2 days. Compared with untreated cells, cells treated with etoposide or doxorubicin 
showed a significant induction in both VDR and p73 transcript levels (Figure 40, top 
panel). As expected, a significant increase in transcript levels of both OPN and OCN 
were observed in cells treated with vitamin D alone (Figure 40, lower panel). 
Interestingly, cells pre-treated with etoposide or doxorubicin and cultured in vitamin D 
for 2 days showed a synergistic increase in both OPN and OCN expression levels that 
were observed with vitamin D treatment alone (Figure 40, lower panel). These results 
suggest that DNA damage induced expression of p73 is responsible for the synergistic 
increase in vitamin D mediated differentiation.  
 Further, to confirm that p73 is essential for DNA damage-mediated enhancement 
in vitamin D mediated differentiation, the transcript levels of OPN and OCN were 
examined in presence and absence of p73 in cells pre-treated with etoposide and 
subsequently with vitamin D. As expected, p73 silencing led to a reduction of VDR 









Figure 41.  DNA damage enhances vitamin D mediated osteoblastic differentiation 
through p73. SaOS2 cells were transfected with either control siRNA or p73 siRNA as 
indicated and treated with 4 µM etoposide or left untreated as indicated. After 24 hrs cells 
were either cultured in control vehicle or 10 nM VD for 48 hrs. Transcript levels of VDR, 
p73, OPN (top panel) and OCN (lower panel) were determined and Y-axis represents the 








indicating that p73 is essential for induction of VDR upon DNA damage in these cells 
(Figure 41). Additionally, silencing p73 also led to a significant decrease in OPN and 
OCN expression levels in cells treated with vitamin D alone or in combination with 
etoposide (Figure 41). In particular, silencing p73 led to a remarkable decrease in OCN 
expression levels in cells treated with vitamin D alone or in combination with etoposide 
(Figure 41). Together, these results clearly suggest that induction of VDR expression by 















A. Significance of VDR regulation by p63 
 Human cancers of epithelial origin comprise eighty percent of solid tumors and 
are preserved through specific subpopulation of stem cells (Visvader and Lindeman, 
2008). The molecular or cellular processes responsible for the origin of epithelial cancers 
are yet to be identified. Particularly, the underlying signaling pathways associated with 
hyper proliferative nature of epithelial cancer stem cells are vastly understudied. In 
contrast to cancers, the epithelial morphogenesis program is associated with coordinated 
regulation of various signaling networks. Therefore, understanding the critical genetic 
paradigms associated with the origin of epithelial tissues will give significant insight on 
the de-regulated cellular factors associated with the initiation of epithelial cancers. The 
initiation and execution of epithelial morphogenesis program has been shown to be 
entirely dependent on transcription factor p63 (Koster et al., 2004). In accordance with 
the role of p63 in epithelial stratification program, p63 null mice lack the tissues of 
epithelial origin. Further, p63 has been shown to determine the differentiation of 
mullerian duct epithelium and loss of p63 expression was shown to result in single 
layered uterine epithelia (Kurita et al., 2004).  
 These studies implicated a critical role for p63 in epithelial tissue formation, thus 
identifying the underlying p63 regulated genetic pathways are subject of intense research. 
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Primarily two different approaches were carried out in identifying such p63 target genes; 
1) p63 deficient cells were overexpressed with specific isoforms of p63 and altered gene 
expression profiles were determined using cDNA profiling assays; 2) endogenous p63 
expression was silenced in p63 containing cells and the gene expression profiles were 
monitored. Each approach has its own advantages and drawbacks, however considerable 
number of p63 regulated genes were determined using these two approaches (Trink et al., 
2007). Similarly, our lab performed a gene expression analysis by over expressing 
TAp63γ isoform in H1299 cells (data not shown). VDR was one of the several hundred 
of genes that were up regulated by TAp63γ in H1299 cells. Nuclear receptor family 
member VDR is a natural receptor for steroid hormone vitamin D. The classical function 
of vitamin D is to maintain the calcium and mineral homeostasis during the bone re-
absorption process. Apart from its classical functions, vitamin D also plays a vital role in 
epidermal differentiation, cell cycle arrest and in immune responses. 
 A substantial induction in VDR expression at protein and transcript levels was 
observed with ectopic TAp63γ in H1299 and HeLa cell (Figure 6). H1299 and HeLa cell 
lines lack a functional p53 protein and ectopic p53 had no effect on VDR expression in 
these cell lines, suggesting that the upregulation of VDR by p63 is independent of p53 
(Figure 6). Several studies were carried out to understand the co-operation and regulation 
between p53 and p63 proteins (Harmes et al., 2003). Although a direct interaction was 
not observed between p63 or p73 and p53, both p63 and p73 were shown to be required 
for the activation of apoptosis related gene promoters by p53 (Davison et al., 1999; Flores 
et al., 2002). These observations suggest that p53 family members can modulate each 
other’s ability to regulate target genes through indirect mechanisms. Interestingly, p53 
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showed no effect on TAp63γ mediated induction of VDR at protein or transcript level 
(Figure 8), indicating that p53 does not have an effect on VDR expression directly or 
indirectly. 
  To understand the functional similarities between p63 and p53, studies were 
carried out to understand the effect of upstream regulators of p53 on p63 (Bergamaschi et 
al., 2004; Bernassola et al., 2005; MacPartlin et al., 2005). While some proteins exerted 
the similar effect on p63 and p53, others showed a differential effect on p63 and p53. For 
example, p14ARF was shown to activate p53 transcriptional activity by sequestering 
MDM2 a negative regulator of p53, p14ARF however was shown to inhibit the 
transcriptional activity of p63 (Calabro et al., 2004; Honda and Yasuda, 1999). In 
transient transfection studies, co-transfection of p14ARF with TAp63γ  resulted in 
substantial down regulation of p63 mediated induction of VDR (Figure 11 & 12). These 
observations highlight VDR as a bona fide target of p63 and additional studies are 
required to decipher the effect of other p53 co-activators on p63 mediated induction of 
VDR.  
 In general, p53 family members activate target genes by binding to canonical p53 
responsive RRRCWWGYYY tandem repeats (Osada et al., 2005). While p53 and p63 
bind to response elements with RRRC(A/T)(A/T)GYYY repeats, response elements 
consisting of RRRCGTGYYY tandem repeats were specifically activated by p63 (Osada 
et al., 2005; Osada et al., 2007). Reports also suggest that sequence differences in the 
response elements might govern the target gene specificity of p53 and p63 proteins 
(Osada et al., 2006; Perez et al., 2007). A significant increase in full length VDR 
promoter activity was observed with ectopic TAp63γ but not with p53 (Figure 7). In 
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addition, deletion of 750 bp fragment from 5’ end of VDR promoter did not abolish p63 
mediated transactivation of VDR (Figure 14). Interestingly, in silico based analysis 
predicted several RRRCGTGYYY tandem repeats within the -635 to -581 region of VDR 
promoter (Figure 14 lower panel). A significant increase in -635/-581 region containing 
reporter activity was also observed with ectopic TAp63γ, suggesting the presence of a 
potential p63 specific responsive element within VDR promoter (Figure 14). Results 
from ChIP analysis clearly demonstrated the binding of ectopic TAp63γ but not p53 on 
VDR promoter in vivo (Figure 13). Moreover, the -635/-581 region of VDR promoter 
was amplified from the p63 immunoprecipitated DNA in the ChIP analysis. These 
observations clearly suggest that p63 activates VDR by binding to a p63 specific 
responsive element within the VDR promoter. 
 Recently adenoviral based gene transfer studies were carried to test the efficacy of 
p53 family members in promoting the growth suppression (Ganjavi et al., 2006; Ishida et 
al., 2000; Sasaki et al., 2001). Particularly, adenoviral based transfer of TAp63γ and 
TAp73β were shown to promote apoptosis and cell cycle arrest in multiple cancer cell 
lines (Das et al., 2005; Kunisaki et al., 2006). Administration of adenoviral-TAp63γ into 
SaOS2-xenografts has been shown to promote the tumor growth retardation much higher 
than that of p53 (Oshima et al., 2007). However, in vitro studies showed a similar level of 
apoptosis induction by both p53 and TAp63γ in SaOS2 osteosarcoma cells (Oshima et al., 
2007). These reports clearly suggest that p63 promotes the growth inhibition of 
osteosarcoma through multiple cellular processes. Results from this study showed a 
significant induction in differentiation of SaOS2 cells with over expression of TAp63 
(Figure 15). Additionally, in SaOS2 cells ectopic p63 up-regulated the transcript levels of 
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VDR and osteoblastic differentiation markers OPN, OCN and RUNX2 (Figure 16).  
Interestingly, osteoblastic differentiation markers OPN, OCN and RUNX2 are shown to 
be the downstream targets of VDR (Bikle, 1992; Koszewski et al., 1996; Noda et al., 
1990). In contrast, both p53 and p63γ (R279H) mutant failed to induce VDR expression 
and differentiation of SaOS2 cells (Figure 14 & 15), suggesting that activation of VDR is 
essential for the effective differentiation of SaOS2 cells. These results indicate that 
TAp63γ promotes the growth inhibition of SaOS2 cells by promoting the differentiation 
through VDR. Vitamin D and its analogues are shown to promote the differentiation of 
SaOS2 cell through VDR (Wu et al., 2007). Interestingly, results from this study showed 
that ectopic p63 sensitizes the SaOS2 cells to the vitamin D mediated differentiation 
(Figure 17). Therefore, adenoviral based gene therapy of p63 in combination with 
vitamin D may be considered for an effective therapeutic strategy against osteosarcoma.  
 The role of p63 in epithelial tissue development, in particular in stratified 
epithelial morphogenesis is well established (Candi et al., 2007). The proliferative 
potential of epithelial stem cells in stratified epithelia is dependent on p63 (Senoo et al., 
2007). The predominant isoforms of p63 observed during development are TAp63α and 
∆Np63α, however the functional relevance of other p63 isoforms still needs to be 
addressed (Koster et al., 2004). Therefore, generation of isoform specific p63 knock-out 
mice and deciphering the isoform specific target genes will give better insight on the 
functional significance of each isoform in development. Vitamin D receptor has also been 
implicated in epidermal differentiation. The ablation of VDR leads to development of 
alopecia due to the defects in hair follicle regeneration (Xie et al., 2002), and reduced 
expression of epidermal differentiation markers including involucrin and loricrin (Bikle 
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et al., 2002; Hawker et al., 2007). Results from this study demonstrated that all the 
isoforms of p63 induce the VDR expression (Figure 18 & 19). Recent genetic 
complementation studies suggested that ∆Np63α isoform by itself does not complement 
epidermal defects in p63-deficient mice, indicating the functional relevance of other p63 
isoforms in development (Candi et al., 2006). Thus it is intriguing to test whether VDR is 
a vital component of both TAp63 and ∆Np63 associated functions during development.  
  The predominant p63 isoform, ∆Np63α is expressed in basal layers of stratified 
epithelia and has been shown to be overexpressed in multiple cancers. ∆Np63α isoform 
is considered to antagonize the functions of p53 and TAp63 by forming hetero-tetramers 
or by competitive binding to specific DNA sequences (Yang et al., 1998). In support of 
this notion, several studies have shown the down regulation of TAp63 mediated 
transactivation by ∆Np63α  (Barbieri et al., 2005; Petitjean et al., 2008). Interestingly, in 
co-transfection studies, while ∆Np63α  down regulated the TAp63 γ mediated induction 
of p21 and IGFBP-3,  ∆Np63α showed no effect on the induction of VDR by TAp63γ 
(Figure 20). This result argues against the assumed dominant negative function for 
∆Np63α towards all the targets that are regulated by TAp63. Although ∆Np63 lacks the 
full length N-terminal TA domain, ∆Np63α isoform has been shown to activate target 
genes transcriptionally (Helton et al., 2006; Wu et al., 2005). Results from transient 
transfection studies clearly showed the induction of VDR expression by ∆Np63α isoform 
at protein and transcript levels (Figure 18 & 19).  Additionally, a significant dose 
dependant increase in VDR-Luc activity with increasing concentrations of ∆Np63α was 
observed, suggesting a direct transcriptional activation of VDR by ∆Np63α isoform 
(Figure 21A). Results from ChIP assay on A431 cells clearly showed the occupancy of 
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∆Np63α protein on the VDR promoter (Figure 21B). Furthermore, silencing endogenous 
∆Np63α  but not ∆Np73α in A431 cells led to complete abolishment in endogenous 
VDR expression (Figure 22). These results strongly suggest VDR as a direct 
transcriptional target of ∆Np63α. 
 The ability of cancer cells to invade is an essential component of metastasis and 
depends upon multiple factors. Recently, down regulation of p63 has been shown to 
increase the cell migration and invasiveness of multiple cancer cells including A431 
(Barbieri et al., 2006; Higashikawa et al., 2007). The active form of vitamin D has also 
been shown to inhibit the invasiveness of prostate cancer cells (Tokar and Webber, 
2005). Results from our studies indeed showed that down regulation of both ∆Np63α and 
VDR results in increased cell migration and invasion (Figure 23). Additionally, 
∆Np63α mediated re-expression of VDR in A431 cells abrogated the increase in 
invasiveness observed with down regulation of p63 or VDR (Figure 24B). Thus, findings 
from this study illustrate a novel role for ∆Np63α in  ligand independent function of 
VDR.  
 Zinc finger transcription factor SNAIL has been shown to promote invasion and 
metastasis by repressing multiple proteins including E-cadherin and ∆Np63α  (Barrallo-
Gimeno and Nieto, 2005; Higashikawa et al., 2007). Interestingly, a direct transcriptional 
activation of E-cadherin by vitamin D has also been shown to promote growth arrest in 
colon cancer cells (Palmer et al., 2001). Finally, VDR has been shown to be repressed by 
SNAIL and a negative correlation between SNAIL and VDR expression has been 
reported in colon cancer cell line (Palmer et al., 2004; Pena et al., 2005). Thus, it is likely 
that at least in A431 cells, SNAIL represses ∆Np63α-VDR-E-cadherin axis to promote 
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invasiveness of cancer cells. A recent report indicated that induction of ∆Np63α protein 
levels by vitamin D is associated with the protection of transformed keratinocytes from 
irradiation mediated stress (Langberg et al., 2009). Interestingly, in A431 cells down 
regulation of VDR resulted in down regulation of endogenous ∆Np63α protein levels 
(Figure 23D). Therefore, it is possible that a feedback regulation of p63 by VDR or vice 
versa might play a vital role in normal functioning of keratinocytes. 
 Several reports implicated a functional role for ligand independent VDR in 
epidermal development (Ellison et al., 2007). Vitamin D receptor has been shown to be 
essential for normal keratinocyte stem cell function and severe epidermal defects were 
observed in vdr-deficient mice (Cianferotti et al., 2007; Xie et al., 2002). However, the 
factors involved in the molecular regulation of VDR during epithelial morphogenesis are 
poorly studied. We observed a marked down regulation of VDR expression levels in p63 
deficient MEF’s and both p63 and VDR were co-localized in basal layers of epidermis in 
newborn wildtype mice (Figure 25 and data not shown). In contrast to wildtype mice, p63 
deficient mice lack well formed skin and a single layer of cells can be observed. 
Histochemical analysis on singe layered p63 deficient mice showed the complete 
abolishment in VDR expression (data obtained from our collaborator Dr. Satrajit Sinha).  
 Although p63 mutations are shown to be responsible for several human 
developmental diseases, the precise molecular mechanisms associated with p63 mutants 
are yet to be identified. Interestingly, we observed a differential effect of naturally 
occurring p63 mutants on VDR expression (Figure 26). Furthermore, p63γ (R279H) 
mutant downregulated the WT TAp63γ mediated induction of VDR (Figure 9 & 10). 
These findings suggest that impairment in VDR regulation by p63 mutants might 
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contribute to the pathophysiology of the diseases. Altogether these results suggest that the 
expression of VDR during embryonic development is dependant on p63 expression. 
However, additional studies are required to understand the precise role of VDR in p63 
mediated functions, in particular in epithelial morphogenesis. In conclusion, results from 
this part of dissertation sheds light on the cross talk between two transcription factors 
∆Np63α and VDR, which might be playing a critical role in invasion and epidermal 
differentiation.  
B. Significance of VDR regulation by p73  
 Identification of new transcriptional networks of p53 family members has given 
significant insight on the functional diversities of each member (Deyoung and Ellisen, 
2007). However, understanding the functional cross talk between each member on basis 
of their binding to common and unique target genes will be crucial in deciphering their 
role in tumorigenesis.  Recently, Maruyama et al (2006) demonstrated VDR as common 
target of p53 family (Maruyama et al., 2006). In contrast, results from our earlier studies 
demonstrated VDR as specific target of p63 (Kommagani et al., 2006). The possible 
explanation for this discrepancy could be the cell line specificity or the amount of p53 
employed for the transient transfection studies. The stability of p53 protein is regulated 
by a negative feedback process through its canonical target MDM2 (Bose and Ghosh, 
2007). Since the transcriptional activity of p53 protein depends on its stability, the dose 
dependent effect of p53 on VDR expression was carried out in p53 null cells.  As 
expected, expression of VDR was not affected by p53 at any of the tested doses (Figure 
27). In addition, elevation of p21 expression by p53 at all the tested doses ruled out the 
possibility of nonfunctional ectopic p53 (Figure 27). Nonetheless, additional in depth 
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functional analysis was required to determine the variability in the outcomes of these two 
groups. 
Although ectopic p53 was unable to induce VDR expression, it does not rule out 
the possibility of VDR regulation by activated p53 upon DNA damage. To test this, we 
carried out in depth analysis of VDR expression upon DNA damage in multiple cancer 
cell lines. Induction of VDR protein expression levels upon DNA damage was observed 
in HeLa , isogenic colon cancer cell lines HCT116 (p53 null) and HCT116 (p53 positive) 
as well as in SaOS2 (p53 null) and U2OS (p53 positive) cells (data not shown), 
suggesting a possible p53 independent activation of VDR upon DNA damage. 
Additionally, in p53 deficient H1299 and SaOS2 cells a significant induction in VDR 
transcript levels was also observed (Figure 28), which suggest that the elevated levels of 
VDR observed upon DNA damage are due to the transcriptional activation of VDR rather 
than the protein stabilization.  
Human cancers display genetic alterations of key components involved in DNA 
damage response signaling pathways, which leads to metastasis and invasiveness 
(Lengauer et al., 1998). Although, p53 has been shown to be inactivated in 50% human 
cancers, several other genes are shown to substitute the p53 functions in multiple cancers 
including p73 (Deyoung and Ellisen, 2007; Levine, 1997). Transcription factor p73 has 
been shown to be induced upon DNA damage in several different cancer cell lines and 
shown to be critical for chemosensitivity of these cells (Chen et al., 2001; Kang et al., 
2002). Interestingly, a strong correlation between p73 and VDR expression at transcript 
and protein levels upon DNA damage was observed in H1299 and SaOS2 cells (Figure 
29). Monitoring the expression of p73 and VDR at multiple time points demonstrated that 
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p73 precedes VDR induction upon DNA damage (Figure 29). As seen with p63, a 
significant induction in VDR expression at transcript and protein levels was also 
observed with multiple isoforms of p73 (Figure 30). Additionally, silencing endogenous 
p73 led to reduction in endogenous VDR levels and endogenous p73 did bind to the VDR 
promoter in vivo, indicating  VDR as a direct transcriptional target of p73 (Figure 31).  
These results clearly suggest a potential role for p73 in DNA damage induced VDR 
expression.  
 Recently a subset of tumor derived mutants of p53 has been shown to inhibit p73 
transcriptional activity through direct physical interaction (Gaiddon et al., 2001; Li and 
Prives, 2007). Additionally, lack of p73 mediated growth suppression has been reported 
in cells harboring p53 mutations (Prabhu et al., 1998) and knock down of p53 mutants 
resulted in enhanced growth suppression of various cancer cell lines (Scian et al., 2004; 
Vikhanskaya et al., 2007).  Ectopic expression of p53 (R248W) mutant resulted in down 
regulation of VDR expression levels observed upon DNA damage, thus indicating the 
requirement of p73 for the induction of VDR upon DNA damage (Figure 32). As 
reported earlier a direct interaction between p73 and p53 (R248W) mutant was observed 
in immunoprecipitation analysis (data not shown). Furthermore, silencing p73 resulted in 
significant reduction in VDR expression observed upon DNA damage (Figure 33). Since 
DNA damage induced VDR expression occurs via p73 and tumor derived mutants 
inhibits this regulation, one should consider the status of both p73 and mutant p53 when 
vitamin D mediated growth inhibitions studies are conducted in human cancer cell lines.  
 It is well documented that vitamin D and its analogues exert their anti 
proliferative activities through VDR and are extensively used for cancer chemotherapy 
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(Banwell et al., 2003; Campbell and Adorini, 2006; Ordonez-Moran et al., 2005; Rashid 
et al., 2001). Since the activity of vitamin D analogues entirely depends on the expression 
levels of VDR (Palmer et al., 2001), p73 mediated induction of VDR upon DNA damage 
should further enhance the vitamin D mediated functions. Pre-treatment of cells with 
etoposide resulted in a substantial increase in vitamin D transcriptional activity (Figure 
35B). Further, down regulation of p73 or VDR expression levels resulted in marked 
decrease in etoposide mediated augmentation of vitamin D transcriptional activity (Figure 
35C). These results suggest that induction of VDR by p73 upon DNA damage can 
sensitize the cells to vitamin D. Additionally, chemotherapeutic agents have been shown 
to stimulate vitamin D mediated biological functions; particularly etoposide and cisplatin 
were shown to stimulate vitamin D mediated differentiation and apoptosis (Hershberger 
et al., 2002; Torres et al., 2000). However, the molecular mechanisms behind this 
stimulation in vitamin D mediated anti-proliferative activates are poorly studied. Since 
p73 is essential for the vitamin D transcriptional activity, it is likely that p73 is essential 
for the stimulation of vitamin D mediated anti-proliferative activates by 
chemotherapeutic agents. Taken together, the results from this study demonstrate a novel 
p73 dependent and p53-independent activation of VDR upon DNA damage.  
Osteoblasts are the main bone forming cells, which are essential for deposition of 
bone extracellular matrix. Osteoblasts derive from pluriopotent mesenchymal cells during 
embryonic development.  The characteristic feature of osteoblasts is that they can be 
cultured in vitro to proliferate and differentiate (Stein et al., 1996). Osteoblastic 
differentiation is essential for proper bone formation and the osteoblastic differentiation 
is mediated by multiple factors including VDR (St-Arnaud, 2008). The role of vitamin D 
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in bone formation and in osteoblastic differentiation is well documented (Yoshizawa et 
al., 1997). Vitamin D has been shown to promote differentiation of mature osteoblasts 
through the regulation of osteoblast associated genes including osteocalcin and 
osteopontin (Matsumoto et al., 1991).  Osteosarcomas are the most common type of bone 
cancers; osteosarcoma cells have characteristics of primary osteoblasts and are widely 
used for studying osteoblasts (Gill and Bell, 2000).  
Vitamin D and vitamin D analogues are in fact shown to promote the 
differentiation of osteosarcoma cells (Barroga et al., 1999; Matsumoto et al., 1998). 
Although vitamin D exerts its biological functions on osteoblasts or osteosarcoma cells, 
the upstream regulation of vitamin D pathway in osteoblasts is still understudied. In this 
study silencing p73 resulted in a significant down regulation of basal VDR expression in 
SaOS2 osteosarcoma cells (Figure 36A). The down regulation of p73 in SaOS2 cells also 
led to the down regulation of vitamin D mediated transcriptional activity (Figure 36B). In 
addition, down regulation of p73 resulted in significant down regulation in vitamin D 
mediated induction of osteopontin and osteocalcin and the differentiation of SaOS2 cells 
(Figure 38). These results clearly suggest a novel upstream regulation of vitamin D 
signaling pathway by p73 in osteosarcoma cells. Transforming growth factor β (TGF-β) 
has also shown to play vital role in bone remodeling (Centrella et al., 1991). Particularly 
TGF-β shown to promote the proliferation of primary osteoblasts and also shown to 
suppress the vitamin D mediated induction of osteocalcin (Kassem et al., 2000). 
Interestingly, transcriptional repression of TAp73 by TGF-β has been reported in 
transformed keratinocytes (Waltermann et al., 2003). Thus, it is likely that TGF-β inhibits 
the vitamin D mediated differentiation of osteoblasts by repressing p73. Furthermore, 
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given both VDR and p73 null mice are runted in phenotype; it is interesting to see 
whether regulation of vitamin D functions by p73 is essential for bone formation during 
embryonic development (Yang et al., 2000; Yoshizawa et al., 1997). 
Vitamin D and its analogues exert anti proliferative actions in different cancer cells 
through VDR and expression of p73 was reported in majority of human cancer cells 
(Muller et al., 2006). In light of results from this study, it is intriguing to see whether p73 
is essential for VDR expression and subsequently for vitamin D mediated biological 
functions in all vitamin D responsive human cancer cell lines. Combinatorial use of 
vitamin D and its analogues with chemotherapeutic agents have shown to be more potent 
in promoting growth inhibition than using them alone (Hershberger et al., 2002; Moffatt 
et al., 1999; St-Arnaud, 2008).  Clinical trials are currently underway, testing the 
combinatorial use of vitamin D analogues and chemotherapeutic agents for cancer 
chemotherapy (Fakih et al., 2007; Trump et al., 2006). Interestingly, a wide range of 
chemotherapeutic agents have been shown to induce the p73 expression levels in multiple 
cancer cells (Irwin et al., 2003; Urist et al., 2004). Results from this study demonstrated 
that regulation of VDR by p73 upon DNA damage can potentiate vitamin D mediated 
differentiation (Figure 40 & 41). Thus, these findings clearly suggest a novel upstream 
regulation of the vitamin D signaling pathway by p73 and provide evidence for the 
requirement of p73 for vitamin D mediated osteoblastic differentiation. Altogether, 
outcomes from this part of study will aid in designing better strategies for combinatorial 
use of chemotherapeutic agents with vitamin D.  
 In conclusion, this dissertation work illustrated the biological significance 



























Figure 42.  Model illustrating the differential regulation of VDR by p53, p63 and 
p73. VDR is activated by both p63 and p73 but not p53. Regulation of VDR by p63 is 
associated with inhibition of invasiveness and possibly in epidermal differentiation. p73 
appears to play a role in vitamin D mediated differentiation by regulating VDR. 
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 and molecular studies demonstrated VDR as a direct transcriptional target of both p63 
and p73. In contrast, p53 had no effect on VDR directly or indirectly. Functional studies 
in A431 cells demonstrated that regulation of VDR by p63 is associated with the 
inhibition of invasiveness. In addition, VDR appears to be regulating the p63 expression 
in A431 cells, suggesting a possible feedback regulation of p63 through VDR. However, 
additional functional studies are required to uncover the role of VDR in p63 mediated 
epidermal differentiation. Furthermore, regulation of VDR by p73 proves to be essential 
for vitamin D mediated osteoblastic differentiation.  Finally DNA damage sensitized the 
cells to vitamin D mediated differentiation through p73. Taken together, these 
observations highlight a novel role for p73 in vitamin D functions and will enhance the 
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